Next Japan 2020 Agenda
ããŒãã£ã«ã€ãã³ã | 2020幎10æ28æ¥-30æ¥
ã¢ãžã§ã³ã
âââââââââââââââââââ
ã»ãã·ã§ã³ãè¬åž«ã«ã€ããŠã¯ãã®ããŒãžã§éææŽæ°ããŠãŸãããŸãããªãè±èªã®ã»ãã·ã§ã³ã«ã€ããŠã¯ãæ¥æ¬èªã«å¹ãæ¿ãããŠãå±ãããããŸãã
å ±ååµç«è ã® Tarek Sherif ãš Glen de Vries ãæè¿ã®æãè¡šããèšåºéçºã®äžçãæ°žé ã«å€ãã1幎ãæ¯ãè¿ããšãšãã«ãMedidata NEXT Global ã®éå¹ãç¥ããŸããããæ¬æ¥ã®ãRave dayãã§ã¯äœãçšæãããŠããããã芧ãã ããããã®åŸãã°ã¬ã³ã»ãã»ãŽãªãŒã¹ãšã¡ãã£ããŒã¿ã®ãããã¯ããªãŒããŒã·ãããšäžç·ã«ããã©ã€ããµã€ãšã³ã¹ã®æªæ¥ããšãæ£è ã®è»¢åž°ãæ¹åããããã®èšåºéçºã®ããžã¿ã«ãã©ã³ã¹ãã©ãŒã¡ãŒã·ã§ã³ã«ãããã¡ãã£ããŒã¿ãš Rave ã®ä»åŸã«ã€ããŠã話ãããŸãã
ã¡ãã£ããŒã¿ãã©ãããã©ãŒã ã«ãã£ãŠå æããä»æ¥ã®èšåºè©Šéšã®èª²é¡
èšåºè©Šéšã®äžçã§ã¯ãè² æ ã®ãããã¯ãŒã¯ãããŒã管çããªããæ¥åå¹çãæ倧åããããšãçŸå®ã®ãã®ãšãªã£ãŠããŸãã äŒæ¥ã¯åžžã«ãããã»ã¹ãåçåããæ°æè¡ã®ã¡ãªããã享åããªãããããè¯ãããŒã¿æŽå¯ãåŸãŠãäžå åããããã¹ã¿ãŒããŒã¿ã掻çšããããŸããŸãªããŒã¿ãœãŒã¹ãåçåããŠãããå€ãã®æ å ±ã«åºã¥ããææ決å®ãæ¯æŽããæ¹æ³ã暡玢ããŠããŸãã
ã¡ãã£ããŒã¿ã§ã¯ãçµ±åãã©ãããã©ãŒã ã®ã¢ãããŒããçšããŠãããŒã¿åéãšç®¡çã«æé©ãªãœãªã¥ãŒã·ã§ã³ãã客æ§ã«æäŸããããåªããŠããŸãã
ãã®ã»ãã·ã§ã³ã§ã¯ã以äžã®å 容ãã玹ä»ããŸãã
- Rave EDC ã®ç解
- ãã©ãããã©ãŒã æŠç¥ãžã®éã®å®çŸ©
- ã¡ãã£ããŒã¿ã®çµ±åãã©ãããã©ãŒã ã«ç§»è¡ããããã®æ§ã ãªãªãã·ã§ã³
- çŸåšMedidata Classic Raveããå©çšäžã®ã客æ§ãžã®é æ ®
- ã¡ãã£ããŒã¿ã®ãã©ãããã©ãŒã ã䜿çšããã¡ãªãã
- ãã©ãããã©ãŒã ãã€ã«ã¹ããŒã³ãžã®é
èŽè¡ã¯ãRave EDC ã®å©ç¹ãåŠã³ããã£ã¹ã«ãã·ã§ã³ã«åå ããŠãã¡ãã£ããŒã¿ã®ãã©ãããã©ãŒã æŠç¥ã«å®éã«é©çšã§ããã¢ã€ãã¢ãåŸãŠåž°ãããšãæåŸ ããŠããŸãã
æ¥çã§ã¯ãèšåºè©Šéšã«æ£è ãšã³ã²ãŒãžã¡ã³ããã€ã³ããœãªã¥ãŒã·ã§ã³ãçµã¿èŸŒãåããå§ãŸã£ãŠããŸããããŸã åºãæ¡çšãããŠãããã®ã¯ãããŸãããè€æ°ã®ãã€ã³ããœãªã¥ãŒã·ã§ã³ãåè©Šéšã§äœ¿çšããããšãã§ããŸãããäžè¬çã«ã¯æ§ã ãªãã³ããŒãæäŸããŠããŸããçµ±äžããããã©ãããã©ãŒã ã¢ãããŒããå©çšããããšã§ãç°ãªããœãªã¥ãŒã·ã§ã³ãçµ±åããããŒã¿ã®ç §åãè¡ãå¿ èŠæ§ãæžå°ããŸãããŸããä»®æ³åããã³/ãŸãã¯æ£è ãšã³ã²ãŒãžã¡ã³ããæäŸããããã«å¿ èŠãªãã³ããŒã®æ°ãæå°éã«æããããéçšãåçåããè€æ°ã®ã·ã¹ãã ã®èšå®ãšç¶æã«ãããã³ã¹ããåæžããããšãã§ããŸãã
ãã®ã»ãã·ã§ã³ã§ã¯ããããªèšªåãeCOAãeConsentãªã©ã®è€æ°ã®ä»®æ³åæè¡ããã¹ãŠåäžã®ãã©ãããã©ãŒã ãéããŠäœ¿çšããŠããµã€ããšæ£è äœéšã®äž¡æ¹ãåäžãããæ¹æ³ãåŠã³ãŸãã
é©çšãšæçã®å éå
éå»äžå¹Žéã«ãå®æœã®ç·Žç¿ã¯äŒæ¥ã®äºæ³ã«é ããŠãããããªã¹ã¯ããŒã¹ã®å質管ç (RBQM) 㯠Biopharma ã®äŒæ¥ã«ãã£ãŠãã倧ããçŠç¹ãæã£ãŠããã RBQM ã®å®æœãšæ¡çšã¯æ§ã ã§ããã COVID-19ã§ã¯ãèšåºè©Šéšã¢ãã¿ãªã³ã°ãžã®åœ±é¿ã倧ãããRBQMã®éèŠæ§ãããã«åŒ·èª¿ããŠããŸãããã®ã»ãã·ã§ã³ã§ã¯ãèšåºç 究çµç¹åäŒïŒACROïŒã«ããæè¿ã®ç 究ãæ¢ããæ°ããªéçºãå«ãæ¥çã® RBQM ã®æ¡çšãè©äŸ¡ããRBQM ã®ãã¹ããã©ã¯ãã£ã¹ã®ããã®ã¬ã€ãã³ã¹ãæäŸããŸãã
ãã®å¯Ÿè©±åã»ãã·ã§ã³ã§ã¯ãåå è 㯠RBQM ã«ã€ããŠã®è©³çŽ°ãåŠã¶ããšãã§ããŸãã
- RBQM ãæ§æããäž»ãªæ§æèŠçŽ ãšæ¡çšãžã®ã¢ãããŒã
- çŸåšã®ã¢ãã¿ãªã³ã°é¢šæ¯ãšCOVID-19以éã®æšç§»
- å šäœç㪠RBQM ã¢ãã«ããã³æè¡
- RBQMã®çŸç¶ãšå°æ¥ã®å§¿
COVID-19ã«ããæè¿ã®æ··ä¹±ãšèª²é¡ãéããŠãäžçã®èŠå¶æ©é¢ã¯ãã³ãããã¯æã®èšåºè©Šéšç®¡çã«é¢ããã¬ã€ãã³ã¹ãçºè¡ããããã®è¿ éãªå¯Ÿå¿ãè¡ã£ãŠããŸããã èšåºè©Šéšã«å¯Ÿããæè¡ãé§äœ¿ãããªã¹ã¯ããŒã¹ã®ã¢ãããŒãã®å®å©äž»çŸ©ãšå容ã¯å®èšŒãããŠããŸãããäžçã平垞ã«æ»ã£ããšãã«ã¯ã©ããªãã®ã§ããããã ã¡ãã£ããŒã¿ã®ã°ããŒãã«ã³ã³ãã©ã€ã¢ã³ã¹ã»æŠç¥æ åœå¯ç€Ÿé·ã§ããã¢ãªã»ãã§ã«ããã³æ°ãšåœŒã®ã°ããŒãã«ãªèŠå¶å°é家ããŒã ããCOVID-19ãèšåºè©Šéšã®å®æœã«é¢ããèŠå¶åœå±ã®ã¬ã€ãã³ã¹ãå€ãããã£ãããšãªã£ãããšã«ã€ããŠè°è«ããŸãã
Acorn AI瀟é·ã®Sastry Chilukuriæ°ãšäžç·ã«ãæšå¹Ž1幎éã«ã¹ãã³ãµãŒãCROãæ¯æŽããããã«Acorn AIãè¡ã£ãé²æ©ã«ã€ããŠã®äŒè©±ã«åå ããŠã¿ãŸãããã
äž»åžå¯ç·ç£ãšã€ããŒã»ã¢ããŒãã·ãŒæ°ãPPDã®ããŒãã³ããŒã·ã£ã«ãªãã£ãµãŒã§ããã¢ã³ã·ã¥ã«ã»ã¿ã¯ã©ã«æ°ãšãPPDã®äŒæ¥éçºãæŠç¥ããã³ãã£ãŒãºã®ã°ããŒãã«ãããã§ããããã·ã»ãã·ã«ãæ°ã
ä»æ¥ã®èšåºè©Šéšã¯ãæ£è åéã®é£ãããã³ã¹ãã®äžæã倱æã®ãªã¹ã¯ã®é«ãŸããªã©ããŸããŸãè€éåããŠããŸããæ²»éšäŸé Œè ã¯ãèšåºéçºããã»ã¹ã®å¹çåãå³ããªãããæåã®ç¢ºçãåäžãããæ¹æ³ã暡玢ããŠããŸãã åæå¯Ÿç §çŸ€ãšã¯ãç¡äœçºåèšåºè©Šéšã®å¯Ÿç §çŸ€ã®ä»£ããã«ãéå»ã®èšåºè©ŠéšããŒã¿ã䜿çšããããšã§ããã ããã«ãããå°æ¥ã®æ£è ã¯ã容èªã§ããªãæšæºæ²»çã§ã¯ãªãæ²»éšè¬ã«å²ãæ¯ãããå¯èœæ§ãé«ããªããããæ£è ã«ãšã£ãŠããé åçãªèšåºè©Šéšãšãªãå¯èœæ§ãããã ãã®æ°ããã¢ãããŒãã¯ãèšåºç 究ã«ãããç§åŠçææ決å®ã匷åããããã«äœ¿çšããããšãã§ãããåæå¯Ÿç §çŸ€ããåŸãããæŽå¯åã掻çšããããšã§ãèšåºéçºã®ãªãŒããŒã¯èšåºè©Šéšãã¶ã€ã³ã«é¢ããŠãããè¯ãæ å ±ã«åºã¥ãããšããã³ã¹ã«åºã¥ããææ決å®ãè¡ãããšãã§ããããã«ãªããŸãã
ãã®ã»ãã·ã§ã³ã§ã¯ã以äžã®ãããã¯ã«ã€ããŠèª¬æããŸãã
- å éšææ決å®ã«ãããSynthetic Control Armâã®ã¡ãªãã
- Synthetic Control Armâã®ãŠãŒã¹ã±ãŒã¹ã®æ€èš
- èšåºè©Šéšã«Synthetic Control Armâãçµã¿èŸŒãéã®éèŠãªèæ ®äºé ãšãã¹ããã©ã¯ãã£ã¹ã確èªããŠãã ããã
COVID-19ãã³ãããã¯ã¯ãèšåºè©Šéšã»ç 究ã®å®æœã«ãããŠã倧ããªåœ±é¿ãäžããŠããŸãããã®ãããªç¶æ³ã«ãããããããç æ°ãæ£ã£ãŠãã人ã«äžæ¥ã§ãæ©ãæ°ããè¬ãå±ããããã«ãç§ãã¡ã¯äœãã§ããããæ¹ããŠèããå¿ èŠããããŸãã
ePROããŠã§ã¢ã©ãã«ããã€ã¹ã䜿ã£ãããŒã¿åéæ¹æ³ã®æŽ»çšã¯ãæ£è ããã®æ¥é¢è² æ ãææçãªã¹ã¯ã®è»œæžãšãã芳ç¹ã§ããŠã£ãºã³ãããã¢ãã¿ãŒã³ããã®èšåºè©Šéšã»ç 究ãæ€èšããã«ããã£ãŠã®éèŠãªãã€ã³ããšãªããŸãã
äžæ¹ãæ£è ããã®æ¥é¢é »åºŠããããŸã§ãããäœããªãè©Šéšã«ãããŠã¯ãã¢ãã¿ãªã³ã°ã«ä»£è¡šããããããªè©Šéšã®å質ç¶æã®ããã®äŸé Œè ãµã€ãã®æŽ»åã䜵ããŠå€é©ããŠããå¿ èŠããããŸãã
æ¬ã»ãã·ã§ã³ã§ã¯ãVirtual TrialãšããããŒã¯ãŒãã«ä»£è¡šãããæ§ã ãªææ³ã掻çšããè©Šéšã®å®æœã«ããã£ãŠãèŠå¶èŠä»¶ã®ååãèžãŸããäžã§ãäž»ã«CRAã®æ¥åã®èŠç¹ããITãäœãæ¯æŽã§ããã®ãããã©ãããã©ãŒã åãããITãœãªã¥ãŒã·ã§ã³æŽ»çšã®ã¡ãªãããäŸé Œè ãèæ ®ãã¹ãããšãªã©ã«ã€ããŠã玹ä»ããŠãŸãããŸãã
COVID-19ãã³ãããã¯ã¯ãèšåºè©Šéšã»ç 究ã®å®æœã«ãããŠã倧ããªåœ±é¿ãäžããŠããŸãããã®ãããªç¶æ³ã«ãããããããç æ°ãæ£ã£ãŠãã人ã«äžæ¥ã§ãæ©ãæ°ããè¬ãå±ããããã«ãç§ãã¡ã¯äœãã§ããããæ¹ããŠèããå¿ èŠããããŸãã
ePROããŠã§ã¢ã©ãã«ããã€ã¹ã䜿ã£ãããŒã¿åéæ¹æ³ã®æŽ»çšã¯ãæ£è ããã®æ¥é¢è² æ ãææçãªã¹ã¯ã®è»œæžãšãã芳ç¹ã§ããŠã£ãºã³ãããã¢ãã¿ãŒã³ããã®èšåºè©Šéšã»ç 究ãæ€èšããã«ããã£ãŠã®éèŠãªãã€ã³ããšãªããŸãã
äžæ¹ãæ£è ããã®æ¥é¢é »åºŠããããŸã§ãããäœããªãè©Šéšã«ãããŠã¯ãã¢ãã¿ãªã³ã°ã«ä»£è¡šããããããªè©Šéšã®å質ç¶æã®ããã®äŸé Œè ãµã€ãã®æŽ»åã䜵ããŠå€é©ããŠããå¿ èŠããããŸãã
æ¬ã»ãã·ã§ã³ã§ã¯ãVirtual TrialãšããããŒã¯ãŒãã«ä»£è¡šãããæ§ã ãªææ³ã掻çšããè©Šéšã®å®æœã«ããã£ãŠãèŠå¶èŠä»¶ã®ååãèžãŸããäžã§ãäž»ã«CRAã®æ¥åã®èŠç¹ããITãäœãæ¯æŽã§ããã®ãããã©ãããã©ãŒã åãããITãœãªã¥ãŒã·ã§ã³æŽ»çšã®ã¡ãªãããäŸé Œè ãèæ ®ãã¹ãããšãªã©ã«ã€ããŠã玹ä»ããŠãŸãããŸãã
泚ïŒQ&Aã¯ã·ã¹ãã éœåã®ããäžæ¢ãšãªããŸããã
ïœOmicsããŒã¿æŽ»çšãã©ãããã©ãŒã ïœ
TissueTech瀟ã¯ãé床ã®ç³å°¿ç æ§è¶³æœ°çã察象ãšãã第3çžèšåºè©Šéšã2020幎3æã«éå§ããäºå®ã§ãã£ãããã¡ããã©COVID-19ãäžçäžã§è©Šéšãéå§ããŠããææã§ãã£ãããã®ç¶æ ã®æ£è ã¯ã5幎åŸã«ã¯åæãæ»äº¡çã50ïŒ ã«ããªãããšããããè©Šéšãå€§å¹ ã«é ãããããšã¯åé¡å€ã§ããã幞ããªããšã«ãTissueTech ã¯ã¡ãã£ããŒã¿ã®çµ±äžãã©ãããã©ãŒã ã§ãã Medidata Rave Clinical Cloud ãæšæºåããŠããããããã³ãããã¯ãçºçããéã«è¿ éã«è©Šéšãå®æœããããšãã§ããŸããããã®ã»ãã·ã§ã³ã§ã¯ãTissueTech ã Medidata Rave Clinical Cloud ã®ãã¯ãŒãã©ã®ããã«æŽ»çšããããã玹ä»ããŸãã
ã»æ²»éšæœèšãšæ£è
ã®èšªåãè¿
éã«ä»®æ³å
ã»ç³å°¿ç
æ§è¶³æœ°çã®éèŠãªãœãŒã¹ããŒã¿ããªã¢ãŒãã§ååŸããã¬ãã¥ãŒãå®æœã
ã»ãã³ãããã¯ã®ããã«å¿
èŠãšããããããã³ã«ã®æŽæ°ãã·ãŒã ã¬ã¹ã«å±é
ã»èšç»çãª100%ãªã³ãµã€ãSDVã¢ãã«ãããªã¹ã¯ããŒã¹ã®ç£èŠæŠç¥ã«ç§»è¡
ãŸããTissueTech ã COVID-19 æéäžã«ã©ã®ããã«ããŠè¿ éã«è©äŸ¡ããæ²»éšå®æœã«é¢ãã FDA ã®ã¬ã€ãã³ã¹ãæºããããšãã§ãããããŸãããã³ãããã¯åŸã®å°æ¥ã®èšåºè©Šéšã®èŠçŽ ãä»®æ³åããããã« Medidata Rave Clinical Cloud ãã©ã®ããã«æŽ»çšããããšããŠãããã«ã€ããŠãã玹ä»ããŸãã
ã¡ãã£ã«ã«ããã€ã¹äŒæ¥ã®äºäŸ
äžççãªå»çæ©åšã¡ãŒã«ãŒã§ãããã¹ãã³ã»ãµã€ãšã³ãã£ãã£ãã¯ç€Ÿã¯ãäžçäžã®æ£è ã®å¥åº·ãåäžãããé©æ°çãªå»çãœãªã¥ãŒã·ã§ã³ãéããŠäººã ã®ç掻ãå€é©ããããšã«å°å¿µããŠãããeConsent ã®å°å ¥ãéžæããŸããã è©Šéšãã¶ã€ã³ãšè©Šéšå®æœã«ãããæ£è äžå¿äž»çŸ©ã®éèŠæ§ã«é¢ããå瀟ã®äžæ žçãªå²åŠã¯ãå€é©çãªãã¯ãããžãŒãéããŠæ£è äžå¿ã®ã€ãããŒã·ã§ã³ãæšé²ãããšããã¡ãã£ããŒã¿èªèº«ã®äžæ žçãªç念ãšå¯æ¥ã«äžèŽããŠããŸããã
ãã¹ãã³ã»ãµã€ãšã³ãã£ãã£ãã¯ç€Ÿã®äž»èŠæå°è ã¯ãèªç€Ÿã®ç 究ã«eConsentãå°å ¥ããéã®äžå¿çãªçŠç¹ã¯æ£è äž»å°ã§ãããšåŒ·èª¿ããŸãããæ£è ãè©Šéšã®ç®çããªã¹ã¯ãå©çãããããç解ããèªåãã¡ã®æš©å©ãšè²¬ä»»ãæåããç解ããããšãã§ããã°ãã¹ãã³ãµãŒã¯æ£è ã«å¯Ÿããå«çç責任ããµããŒãããŠãããšæããæçµçã«ã¯ããè¯ãç§åŠã«ã€ãªãããšèããŠããŸããã æ²»éšäŸé Œè ã®ç¬¬äºã®é¢å¿äºã¯ãéäžç£èŠãååæãç»é²å ±åãªã©ã®æ¥åå¹çåãèªèããããšã§ãã£ãã
ãã®ã»ãã·ã§ã³ã§ã¯ä»¥äžã®å 容ãåãäžããŸãã
- eConsentãã©ã®ããã«ããŠæ£è äžå¿ã®ã¢ãŠãã«ã ãšãªãã¬ãŒã·ã§ãã«ãšã¯ã»ã¬ã³ã¹ãä¿é²ããã®ãã
- è€æ°ã®ã¹ãã³ãµãŒãšè€æ°ã®ç 究ãéããŠæããã«ãªã£ãeConsentã®äž»ãªå©ç¹ã
- å»çæ©åšç 究ã«ããããã¹ãã³ã»ãµã€ãšã³ãã£ãã£ãã¯ç€Ÿã®å°å ¥äºäŸã
èšåºè©Šéšã§ã¯ã¢ãã€ã«ã»ã³ãµãŒããŠã§ã¢ã©ãã«ã»ã³ãµãŒã®æ¡çšãå¢ããŠãããæ²»éšäŸé Œè ãããŒãããŒã«ã¹ã±ãŒã©ãã«ã§ãããŒã¿æšæºã䜿çšããŠãšã³ããã€ã³ãããµããŒãããæ°èŠçºèŠãä¿é²ããæè¡ãæäŸããããšã極ããŠéèŠã«ãªã£ãŠããŸããæ¬ãã¬ãŒã³ããŒã·ã§ã³ã§ã¯ãã¡ãã£ããŒã¿ã® Rave Wearable Sensorsãã©ã®ããã«é©åãããã説æããŸããã¡ãã£ããŒã¿ãã©ã®ããã«ããŠé«ã粟床ãæã€ã®å»çã°ã¬ãŒãããŒã¿ã®ããã®åºç€ãšãªãã»ã³ãµãŒããŒã¿ãã©ãããã©ãŒã ãæ§ç¯ããŠããã®ãããŸãæ¥çåã®ã»ã³ãµãŒçšå ±éããŒã¿ã¢ãã«ãå°å ¥ããŠããã®ãã«çŠç¹ãåœãŠãŸãã
ç 究çµäºã¡ãã£ã¢ã®ããã»ã¹ã¯ãã¹ãã³ãµãŒããµã€ãã«ãšã£ãŠéåžžã«è€éã§æéã®ããããã®ã«ãªãå¯èœæ§ããããŸãã çŸåšã®ç 究çµäºã¡ãã£ã¢ããã»ã¹ãžã®ã¢ãããŒãã¯ã15ã¹ããã以äžã®ããã»ã¹ã«ãªãå¯èœæ§ããããŸãã ãã®ããã»ã¹ããç©ççãªã¡ãã£ã¢ãäœæã»é åžããããçŽã®åé 蚌ãåŠçããå¿ èŠããªãããŠãããã3ïœ4ã¹ãããã«æŽçããããšãã§ãããšãããã©ãã§ããããã ã¡ãã£ããŒã¿ã®Site Cloud End of Studyãªãããããå¯èœã§ãã å®å šã§ä¿¡é Œã§ããçµ±åãã©ãããã©ãŒã ãä»ããŠããã¹ãŠãã·ãŒã ã¬ã¹ã«å®è¡ãããŸãã ãã®ã»ãã·ã§ã³ã§ã¯ãSite Cloud. End of Study 補åãšãã®å°å ¥ããã»ã¹ãæ¢ãã»ãã·ã§ã³ã«ãåå ãã ããã ã¡ãã£ããŒã¿ã®è£œåãšãµãŒãã¹ããæ²»éšçµäºãŸã§ã®ããã»ã¹ãåçåããæ²»éšäŸé Œè ãšCROã®ããŒã¿ã®æŽåæ§ãç¶æããŠãããšãã話ããèããã ããã
ãã®ã»ãã·ã§ã³ã§ã¯ã以äžã®ç¹ãæ€èšããŸãã
- æ²»éšçµäºãŸã§ã®ããã»ã¹ã«ãããäžè¬çãªèª²é¡
- å®è£ ã©ã€ããµã€ã¯ã«
- æäœæ¥ã«ããã¡ãã£ã¢é ä¿¡ã»ç®¡çããé»ååãžã®ç§»è¡ã®å¹æ
- åŠç¿çµäºææžããã¹ãŠé»ååããŠå ±æãããã©ãããã©ãŒã ã掻çšããã¡ãªãã
ãããœãŒã»ã·ã¹ãã ãºãšãœãŒãã»ãªãŒããŒã·ããã»ãã€ãžããããããããœãŒã»ã·ã¹ãã ãºã®åç· åœ¹å¯äŒé·å ŒCEOã®ãã«ãã«ãã»ã·ã£ã«ã¬æ°ããã³ã³ã»ããããåæ¥åãŸã§ãã©ã€ããµã€ãšã³ã¹ç£æ¥ã®å°æ¥åãæ¢ããŸãããã®åŸããããœãŒã»ã·ã¹ãã ãºãšã¡ãã£ããŒã¿ã®ãªãŒããŒãã¡ãšäžç·ã«ãäžççãªå€§æµè¡ãæ°æè¡ã®æ¡çšãå éãããç 究ã³ãã¥ããã£ãèšåºéçºã«ã€ããŠã©ã®ããã«èããŠãããã«ã€ããŠè°è«ããŸãã
æåããããããããŒãããŒã·ãã
å»è¬åç 究ãæ°ããªããŒã¿ã®æªæ¥ãžãšç§»è¡ããäžãããŒã¿ã®åéãä¿åãåæãè¡ãããã® eClinical 補åã®æ®åã¯ãå»è¬åéçºæ¥ååèšæ©é¢ïŒCROïŒã«ç¬ç¹ã®èª²é¡ãæ瀺ããŠããŸããå Žåã«ãã£ãŠã¯ãCROã¯è©Šéšã®éçšã§20以äžã®eClinicalã·ã¹ãã ã䜿çšããŠãããã¹ãã³ãµãŒãæœèšãããã«ã¯ç€Ÿå ã®ããŒã ã¡ã³ããŒãšå¹æçã«ã³ã©ãã¬ãŒã·ã§ã³ããããšãå°é£ã«ãªãããšããããŸãã
ãã®ã»ãã·ã§ã³ã§ã¯ãSyneos Health ã Medidata Rave Clinical Cloud ãšããŠç¥ãããã¡ãã£ããŒã¿ã®çµ±åãã©ãããã©ãŒã ãã©ã®ããã«æŽ»çšããŠãããã®èª²é¡ãå æããã¹ãã³ãµãŒãæ°è¬ãããæ©ãåžå Žã«æå ¥ãããã®éçšã§ããžãã¹ãæé·ãããããšã«æåããããã玹ä»ããŸãã
ã·ããªã¹ã¯ãMedidata Rave ã¯ãªãã«ã«ã¯ã©ãŠãã®äžéšã§ããã¡ãã£ããŒã¿è£œåã®æšæºåãã©ã®ããã«åœ¹ç«ã£ããã説æããŸãã
- çµç¹ãšã¹ãã³ãµãŒã«äŸ¡å€ãæäŸ
- ãã¹ãŠã®æ²»éšé¢ä¿è ãšã®é£æºã匷åãã
- ã¹ãã³ãµãŒãç 究ç®çãéæããããã®æ¯æŽ
- æ¢å顧客ãæ°èŠé¡§å®¢ãšã®ããžãã¹ãæé·ããã
ãããžã§ã¯ãALSãšã®ã³ã©ãã¬ãŒã·ã§ã³
ALSïŒçèçž®æ§åŽçŽ¢ç¡¬åçïŒã¯é²è¡æ§ã®ç¥çµå€æ§çŸæ£ã§ãäœãåããããã話ããããé£ã¹ãããåŒåžãããããèœåã倱ãããŸããç±³åœã§ã¯çŽ3äžäººã眹æ£ããŠãããæ²»çæ³ã¯ãªãã蚺æåŸ2ïœ5幎ã§æ»äº¡ããã®ãäžè¬çã§ããéºäŒçèŠå ãç°å¢çèŠå ã®ç解ã¯é²ãã§ããŸãããALSã®åå ãã»ãšãã©è§£æãããŠããªããããç 究ãå¹æçãªæ²»çæ³ãèŠã€ããã®ãé£ããç æ°ã§ããããšã«å€ããã¯ãããŸããã
Project ALS ã¯éå¶å©å£äœã§ãæãææãªç§åŠçã»å»åŠçç 究ãç¹å®ããŠè³éãæäŸããããè¯ãæ²»çæŠç¥ãéçºããALS ã®æåã®å¹æçãªæ²»çæ³ãšæ²»çæ³ã®ç¹å®ã«åããŠæŽ»åããŠããŸãã
ã¡ãã£ããŒã¿ã®Acorn AIã¯ãã®ã»ã©ãProject ALSãšã®å ±åç 究ãéå§ããŸããããã®å€é¢çãªå ±åç 究ã¯ãåžå°çŸæ£ãæ£ã£ãŠãã人ã ã®ALSã®çŸæ£ããã»ã¹ã«ã€ããŠã®ç解ãæ·±ããããšãç®çãšããŠããŸãã ãã®ã»ãã·ã§ã³ã§ã¯ã以äžã®å 容ãåãäžããŸãã
- Project ALS éåã®èšç«ãšãç§åŠãšå»åŠã ALS ãšé¢é£çŸæ£ã®ç 究ã«åãçµãæ¹æ³ãžã®å€é©çãªã¢ãããŒã
- ALSåµè¬ã®ããŒãºãšèª²é¡
- ç 究ååã®é²å±ãšãèšåºäžã®ããŒãºãé«ããæºããããŠããªãæ£è ããã«äŸ¡å€ãæäŸããããã®ãã«ãã»ã¯ã¿ãŒã»ã¹ããŒã¯ãã«ããŒã®èŠç¹ã®éèŠæ§
- ãã€ãªããŒã«ãŒçºèŠããŒã«ã«ããALSæ²»çãžã®ç²Ÿå¯å»åŠçã¢ãããŒã
Glen de Vries ã¯ãäžçäžã§æãå©çšãããŠããèšåºè©Šéšãã©ãããã©ãŒã ã§ããã¡ãã£ããŒã¿ã®å ±åæé«çµå¶è²¬ä»»è ïŒCEOïŒå Œå ±ååµç«è ã§ããã¡ãã£ããŒã¿ã¯æ°äžä»¶ã®èšåºè©Šéšãæšé²ããæ°çŸäžäººã®æ£è ãšæ°åå件ã®æ£è èšé²ãä¿æããŠããŸãã2019幎ãã¡ãã£ããŒã¿ã¯å²äžæ倧èŠæš¡ã®ãã«ã¹ã±ã¢æè¡ã®è²·åã§ããããœãŒã»ã·ã¹ãã ãºã®åäžã«å ¥ããŸãããã°ã¬ã³ã¯1999幎ã®ã¡ãã£ããŒã¿ã®åµæ¥ä»¥æ¥ããã¯ãããžãŒãéäŒçµ±çãªèãæ¹ãæ¥çã®ã³ã©ãã¬ãŒã·ã§ã³ãé§äœ¿ããŠå»è¬åããžãã¹ã®å€é©ãæšé²ããããšã§ããããã¹ããŒããªæ²»çãšããå¥åº·ãªäººã ãå®çŸããããšããã¡ãã£ããŒã¿ã®ããã·ã§ã³ãæšé²ããŠããŸãããã°ã¬ã³ã®èæžã¯ãApplied Clinical TrialsãCancerãThe Journal of UrologyãMolecular Diagnosticsããã®ä»ã®ãžã£ãŒãã«ã«æ²èŒãããŠããŸããã«ãŒãã®ãŒã¡ãã³å€§åŠã®è©è°å¡ãåããŠããããThe Patient EquationãïŒde Vries & Blachman, 2020ïŒã®èè ã§ããããŸããã°ã¬ã³ã¯ã«ãŒãã®ãŒã¡ãã³å€§åŠã§ååçç©åŠãšéºäŒåŠã®åŠå£«å·ãååŸããã³ãã³ãã¢é·è掟å»çã»ã³ã¿ãŒã§ç 究å¡ãåãããã¥ãŒãšãŒã¯å€§åŠã®ã¯ãŒã©ã³ãæ°åŠç 究æã§ã³ã³ãã¥ãŒã¿ãµã€ãšã³ã¹ãåŠãã ãã
å±±æ¬ã¯æ¥æ¬æ³äººã®ä»£è¡šåç· åœ¹ãšããŠãæ¥æ¬åžå Žã«ãããã¡ãã£ããŒã¿ã®äºæ¥ãçµ±æ¬ããŠããŸãã2005幎ã«æ¥æ¬æ³äººãèšç«ãããŠä»¥æ¥ãã¡ãã£ããŒã¿ã®æ¥æ¬ã«ãããå¶æ¥ã»ããŒã±ãã£ã³ã°ãã¯ããå¹ åºãæ¥åã®ç«ã¡äžããéå¶ãçµ±çããŠããŸãããããã«ã¯ãäžåœãéåœãã·ã³ã¬ããŒã«ãšãã£ãã¢ãžã¢ååœã«ãããããžãã¹ã®ç«ã¡äžã責任è ãšããŠãåŸäºããŸããã倧åŠåæ¥åŸã«ãæ ªåŒäŒç€ŸCSKïŒçŸSCSKïŒã«å ¥ç€ŸãããœãããŠã§ã¢éçºæè¡è ãšããŠãå¹ åºãåéã®èšåºãœãããŠã§ã¢ã·ã¹ãã éçºã®èšèšãšããã°ã©ãã³ã°ã«åŸäºããŸãããäŒè€å¿ ãã¯ããµã€ãšã³ã¹ã°ã«ãŒãïŒçŸäŒè€å¿ ãã¯ããœãªã¥ãŒã·ã§ã³ãºã°ã«ãŒãïŒãžç§»ã£ãåŸã補è¬äŒæ¥ã®R&Dã察象ãšããã·ã¹ãã ã€ã³ãã°ã¬ãŒã·ã§ã³äºæ¥ãçµ±æ¬ããŸããã以æ¥ã20幎以äžã«ããã£ãŠãèšåºéçºåãã®ãã¯ãããžãŒã®æ®åã«åŸäºããŠããŸãããåè倧åŠã§çç§æè²åŠå£«å·ãååŸããŠããŸãã
ã¢ã³ãœããŒã¯ã¡ãã£ããŒã¿ã®ã¢ãã€ã«ãã«ã¹æ åœã·ãã¢ãã€ã¹ãã¬ãžãã³ãã§ããã¢ã³ãœããŒã¯20幎åã«Genentechã§èšåºç 究ã®ãã£ãªã¢ãã¹ã¿ãŒããããåŸãNextrials(PRAHealthSciencesãè²·å)ãMytrus(åŸã«Medidataãè²·å)ãªã©è€æ°ã®èšåºè©Šéšãã¯ãããžãŒã®æ°èäŒæ¥ãå ±åèšç«ããŸããããããŸã§ã®ãã£ãªã¢ã®äžã§ãæ£è ãæœèšãã¹ãã³ãµãŒã®ããã«èšåºè©Šéšãç°¡çŽ åããç Žå£çã§é©æ°çãªæè¡ã«çŠç¹ãåœãŠãŠããŸãããPharmaVoiceã®ãèšåºç 究ã§æãåºæ¿çãªäººç©ããã100ãã«éžã°ããèšåºããŒã¿ç®¡çåŠäŒã®çäºé·ãåããçŸåšã¯AppliedClinicalTrialsèªã®ç·šéå§å¡äŒã®ã¡ã³ããŒãåããŠããŸãããŸããèšåºç 究ã«ãããæè¡ã®å¹ççãªå©çšã«é¢ãããããã¯ã«ã€ããŠã®å·çãçºè¡šãé »ç¹ã«è¡ã£ãŠãããã«ãªãã©ã«ãã¢å€§åŠããŒã¯ã¬ãŒæ ¡ã§ç€ŸäŒåŠã®åŠäœãååŸããŠããŸãã
Tarek ã¯ããããœãŒã»ã·ã¹ãã ãºã®ã¡ãã£ããŒã¿ç€Ÿã®å ±åæé«çµå¶è²¬ä»»è ïŒCEOïŒå Œå ±ååµæ¥è ã§ããã¡ãã£ããŒã¿ãæ°èäŒæ¥ããã©ã€ããµã€ãšã³ã¹æ¥çåãã¯ã©ãŠãããŒã¹ã®ãœãªã¥ãŒã·ã§ã³ãæäŸãããªãŒãã£ã³ã°ã»ã°ããŒãã«ã»ãããã€ãã«æé·ããããã¥ãŒãšãŒã¯åžã§èšç«ããããã¯ãããžãŒäŒæ¥ãšããŠã¯æ倧çŽã®èŠæš¡ãèªããŸããã¡ãã£ããŒã¿ã¯èšåºè©ŠéšããŒã¿ã®åéã»ç®¡çã«ãããã°ããŒãã«ãªãŒããŒã§ããã120ã«åœä»¥äžã§èšåºè©ŠéšããµããŒãããäžæ¹ãåçŽåã¯ã©ãŠãäŒæ¥ã®ããžãã¹ã¢ãã«ãå®çŸ©ããŠããŸããã¿ã¬ãã¯ã¯2020幎ããããœãŒã»ã·ã¹ãã ãºã®ã©ã€ããµã€ãšã³ã¹ã»ãã«ã¹ã±ã¢éšéã®äŒé·ã«å°±ä»»ããŸãããTarek ã¯ãå»çæè¡ãšéèã®åé㧠30 幎以äžã®ãªãŒããŒã·ããçµéšãæã£ãŠããŸããã¡ãã£ããŒã¿ã«å ¥ç€Ÿããåã¯ãå ¬éã»éå ¬éæè¡ã»ã©ã€ããµã€ãšã³ã¹äŒæ¥ã察象ãšãããšã¯ã€ãã£ãã¡ã³ãã®å ±åçµå¶ã»ç®¡çãè¡ããšãšãã«ãéèåéã§ããŸããŸãªåœ¹è·ãæŽä»»ããŸããã1984幎ã«ãšãŒã«å€§åŠã§çµæžåŠã®æåŠå£«å·ãååŸãã1991幎ã«ã³ãã³ãã¢ã»ããžãã¹ã»ã¹ã¯ãŒã«ãåæ¥ããçµå¶åŠãšè²¡åã®åŠäœãååŸããŸããããã¥ãŒãšãŒã¯åžæ°ã®ããã®ããžãã¹æ©äŒãšéçšã®åµåºã«åãå ¥ããŠãããã¥ãŒãšãŒã¯åžããŒãããŒã·ããåºéã®å ±åè°é·ãåããŠããŸããã¿ã¬ãã¯ã¯ãŸãã極å°ãžã®æè²çé åŸãéããéå°å¹Žã®åºæ¿ã«çŠç¹ãåœãŠãéå¶å©å£äœãStudents on Iceãã®è«®åå§å¡äŒãããã¥ãŒãšãŒã¯å€§åŠã©ã³ãŽãŒã³å»çã»ã³ã¿ãŒã®çéªšæ Œç³»è«®åå§å¡äŒã®å§å¡ãåããŠããŸãã
ãªãµã¯ãã¡ãã£ããŒã¿ã®ãªã¹ã¯ã«åºã¥ãå質管çïŒRBQMïŒæ©èœã®è£œåæ åœãã€ã¹ãã¬ãžãã³ãã§ãã補è¬ããã€ãªãã¯ãããžãŒãå»çæ©åšæ¥çã§20幎è¿ãã®çµéšãæã¡ãèšåºè©Šéšã®åè¶ããå®æœããµããŒãããããã®è€éãªã·ã¹ãã ãœãªã¥ãŒã·ã§ã³ãæäŸããŠããŸããAmgen瀟ã§ã¯ãã³ã³ãµã«ãã£ã³ã°ãšæ å ±ã·ã¹ãã ãªãŒããŒã·ããã®äž¡æ¹ã«åŸäºããèšåºè©Šéšç®¡çãšã³ã·ã¹ãã ã®ã¢ãŒããã¯ãã£ãšéçºããªãŒãããŸãããAmgen瀟ã§ã¯ãTransCelerateBiopharma瀟ã§ãªãŒããŒã·ãããçºæ®ããå ±ææ²»éšè¬ãã©ãããã©ãŒã ãšæ²»éšè¬ã¬ãžã¹ããªã®æäŸãéããŠæ¥çã®ã€ãããŒã·ã§ã³ãæšé²ããŠããŸãããåã«ãªãã©ã«ãã¢å€§åŠã§çç©å»åŠ/çååŠå·¥åŠã®çåŠå£«å·ãååŸããŠããŸãã
Gary Thompson, MS ã¯ãã¡ãã£ããŒã¿ã»ãœãªã¥ãŒã·ã§ã³ãºã®æŠç¥ã³ã³ãµã«ãã£ã³ã°æ åœãã€ã¹ãã¬ãžãã³ãã§ã顧客ãã¡ãã£ããŒã¿ã®ãã©ãããã©ãŒã ããæ倧éã®äŸ¡å€ãåŒãåºããå€é©çãªããžãã¹ç®æšãéæã§ããããæ¯æŽããŠããŸãã Gary Thompson æ°ã¯ãèšåºç 究åéã«ãããŠãCROã補è¬ããã¯ãããžãŒäŒæ¥ã®æ§ã ãªèšå®ã§25幎以äžã®çµéšãæã£ãŠããŸããã¡ãã£ããŒã¿ã«å ¥ç€Ÿããåã¯ããªãªãŒç€Ÿã®èšåºããŒã¿ç§åŠæ åœã·ãã¢ãã£ã¬ã¯ã¿ãŒãšããŠããªãªãŒç€Ÿã®èšåºããŒã¿ç®¡çãeSourceãäžå€®ç£èŠæ©èœãã°ããŒãã«ã«æ åœããŠããŸããã ãããŸã§ã®ãã£ãªã¢ã®äžã§ãããŒã¿ç®¡çã»ããŒã¿ãµã€ãšã³ã¹ãèšåºæ©èœéçºãçµ±èšæ¥åã«é¢é£ããæ°å€ãã®æå°ç圹å²ãæ ã£ãŠããŸããã ãããŸã§ã®çµéšã¯ãèšåºè©ŠéšããŒããã©ãªãªã®æäŸãæŠç¥çãœãŒã·ã³ã°ããªã¹ã¯ããŒã¹ã®èšåºéçºãããã»ã¹ãšæè¡ã®éçºãšå®è£ ãããŒã¿ãåæãèªååãéããèšåºéçºã®å€é©ã«çŠç¹ãåœãŠãŠããŸããçç©å»åŠå·¥åŠã®ä¿®å£«å·ãååŸããŠããŸãã
ã¡ãªããµã¯ãã¡ãã£ããŒã¿ã»ãœãªã¥ãŒã·ã§ã³ãºã®ãããŒãžã³ã°ã»ããªã³ã·ãã«ã»ãšã³ã²ãŒãžã¡ã³ãã»ã³ã³ãµã«ã¿ã³ãã§ããã¡ãªããµã¯ãã°ããŒãã«ãªèšåºè©Šéšçµç¹ã§19幎以äžã®çµéšãæã¡ããã¯ãããžãŒã掻çšããèšåºè©Šéšã®å¹çåãšäŸ¡å€ã®åäžã«åãçµãã§ããŸããã¡ãã£ããŒã¿ã§ã¯ãèšåºéçºã«ããã顧客ãžã®ã³ã³ãµã«ãã£ã³ã°ããã¬ãŒãã³ã°ããµããŒããæ åœããŠãããç¹ã«è©Šéšå®æœãšããŒã¿åæã®åŽé¢ãæ±ã£ãŠããŸããã¡ãªããµã¯ãæ°å¹ŽåããPhUSEæ¥çå£äœå ã®ããŒã¿å¯èŠåã»åæã¯ãŒãã³ã°ã°ã«ãŒãã®å ±åãªãŒããŒãåããSCDMãšDIAçµç¹ã®æŽ»çºãªã¡ã³ããŒãšããŠã掻èºããŠããŸããã¡ãã£ããŒã¿ã«å ¥ç€Ÿããåã¯ãã¡ã«ã¯ç€Ÿã§ããŒã¿ãããŒãžã£ãŒããã³ãã¯ãã«ã«ã¢ããªã¹ããšããŠãã¹ã¿ãã£ã®æ§ç¯ãã©ããã³ããŒã®ç®¡çãePROæè¡ã®ãµããŒããå»çã³ãŒãã£ã³ã°ããŒã ã®ææ®ãæ åœããŠããŸãããã©ãã¬ãŒã¹å€§åŠã§ã³ã³ãã¥ãŒã¿ãµã€ãšã³ã¹ã®çåŠå£«å·ãååŸããã¹ãã£ãŒãã³ã¹å·¥ç§å€§åŠã§æè¡ç®¡çã®ä¿®å£«å·ãååŸããŠããŸãã
Anina Adelfio ã¯ãAssociation of Clinical Research Organizations (ACRO) ã®æ¥çé¢ä¿æ åœå¯ç€Ÿé·ã§ããACRO ã¯ãäžçããªãŒãããèšåºç 究ããã³æè¡å£äœã代衚ããŠããŸããAninaã¯ãTransCelerate Biopharmaãäžå¿ãšããæ¥çå£äœãšã®äº€æµã®ããã«èšçœ®ãããACROã®æ¯éšã§ããCROãã©ãŒã©ã ããµããŒãããŠããŸãã2015幎以æ¥ã圌女ã¯ACROã®Risk Based Quality Managementå§å¡äŒããµããŒãããRBMãšRBQMã®æ¡çšãä¿é²ããããã«æ¥çå šäœãããªãããªã³ãªãŒããŒãéããŠããŸããAninaã¯ã¯ã·ã³ãã³DCã®ããŠã³ã¿ãŠã³ã«å€«ãšæšæºçãªããŒãã«ã®Kikiãšäžç·ã«äœãã§ããŸãã
ãã©ã€ã¢ã³ ã¯ã補åéçº – RBQM ã®ãã£ã¬ã¯ã¿ãŒã§ããã¡ãã£ããŒã¿ã«å ¥ç€Ÿããåã¯ãCRO ã®åé㧠14 幎éå€åããéå»7幎éã¯RBMããµããŒãããäžå°ãã倧èŠæš¡ãªè£œè¬äŒç€Ÿããã€ãªè£œè¬äŒç€Ÿããã€ãªãã¯ãããžãŒäŒæ¥ã®RBMéçšåã«ç¹åããŠããŸããããã©ã€ã¢ã³ã¯ãAssociateofClinicalResearchOrganizations(ACRO)RBQMWorkingGroupã®å ±åãªãšãŸã³ã§ãããå€ãã®æ¥ç㧠RBQM ã®ãããã¯ã«ã€ããŠè¬æŒã»çºè¡šãããŠããŸãã
ãåŸ ããããŸããã2020: Phil Coran ã¯ãã¡ãã£ããŒã¿ã»ãœãªã¥ãŒã·ã§ã³ãºã®ã°ããŒãã«ã³ã³ãã©ã€ã¢ã³ã¹ïŒæŠç¥æ åœããªã³ã·ãã«ã§ãããã£ã«ã¯ãç±³åœFDAãEMAãªã©ã®èŠå¶åœå±ãšå€ãã®ãããšããããŠããŸããã ã¡ãã£ããŒã¿ã«å ¥ç€Ÿããåã¯ããã¡ã€ã¶ãŒã§å»çå質ä¿èšŒéšéã«12幎éå€åããæ°å件ã®GCPæœèšç£æ»ïŒå šäžçïŒãšæè¡ã³ã³ãã©ã€ã¢ã³ã¹ç£æ»ãå®æœããŸããããã£ã«ã¯æ å ±ã·ã¹ãã ç£æ»äºº (CISA) ããã³ãã©ã€ãã·ãŒå°é家 (CIPP/US) ã®è³æ Œãæã¡ããã©ãŒãã 倧åŠããŒã¹ã¯ãŒã«ã§æ³åŠå士å·ãååŸããã¯ã·ã³ãã³å€§åŠã§ MBA ãååŸããŠããŸãããã¥ãŒãšãŒã¯ããã³ã«ãªãã©ã«ãã¢å·åŒè·å£«äŒã®ã¡ã³ããŒã§ãããGCPãæ°æè¡ãå«ãèšåºè©Šéšé¢é£ã®ãããã¯ã«ã€ããŠé »ç¹ã«è¬æŒãè¡ã£ãŠãããClinical Trials Transformation Initiative (CTTI) Mobile Clinical Trials ãããžã§ã¯ãã®ããŒã ãªãŒããŒãåããŠããŸãã
ã¢ãªæ°ã¯ãã¡ãã£ããŒã¿ã®ã°ããŒãã«ã³ã³ãã©ã€ã¢ã³ã¹ïŒæŠç¥éšéã®ãªãŒããŒãšããŠããªã¹ã¯ããŒã¹ã®ã¢ãããŒããæ¡çšããèšåºè©Šéšãšã³ã·ã¹ãã ã®ã°ããŒãã«ãªèŠå¶ç¶æ³ãããã²ãŒããã解éããŠããŸããèŠå¶å¯Ÿè±¡æ¥çã§20幎è¿ãã®çµéšãæã€ã¢ãªæ°ã¯ãæ©èœæšªæçã«çµ±åããå質管çã·ã¹ãã å ã§ã¬ããã³ã¹ããªã¹ã¯ãã³ã³ãããŒã«ã®ãã©ã³ã¹ã®ãšããé©çšãå®çŸããŸããåœéçãªããŒã ã®çµéšã掻ãããã¡ãã£ããŒã¿ã¯ãªãã«ã«ã¯ã©ãŠãã®å¯èœæ§ãæ倧åããäžã§æãéèŠãªåéã«ã€ããŠãä¿¡é Œæ§ãšéææ§ã®åäžãç©æ¥µçã«æšé²ããŠããŸãã
ãã£ãªãã¯ãã¡ãã£ããŒã¿ã®ã°ããŒãã«ã³ã³ãã©ã€ã¢ã³ã¹ã»æŠç¥ããªã³ã·ãã«ã§ãããã£ãªãæ°ã¯çŸåšãã©ã€ããµã€ãšã³ã¹ã»ãã«ã¹ã±ã¢æ¥çãç¹ã«èšåºç 究é åã«åœ±é¿ãäžããæè¡é²æ©ã®èŠå¶é¢ãšçžãŸã£ãŠãGxPé¢é£ã®èŠå¶å€æŽã®è©äŸ¡ã«éç¹ã眮ããŠããŸãããã®åœ¹å²ã«ãããŠããã£ãªãã¯ãç¹ã«æ£è äžå¿ã®æè¡ãäžå¿ãšããææ°æè¡æŠç¥ã«ã€ããŠãåœå±ãæ¥çå£äœãšå®æçã«äº€æµãè¡ã£ãŠããŸãããã£ãªãã¯çŸåšãACROã®Decentralised Clinical Trials Working Partyã®è°é·ãåããŠããŸãããã®æ¥çã°ã«ãŒãã¯åœå±ãšç·å¯ã«é£æºãããšã³ãããŒãšã³ãããã»ã¹ã®ãã¬ãŒã ã¯ãŒã¯ãšãã¹ããã©ã¯ãã£ã¹ããã¶ã€ã³ã«ããå質ã¬ã€ãã³ã¹ãåæ£åèšåºè©Šéšã®ãªã¹ã¯è©äŸ¡åºæºã®éçºã«çŠç¹ãåœãŠãŠããŸãã ã¡ãã£ããŒã¿å ¥ç€Ÿä»¥åã¯ãããã€ãã®ãã£ã¬ã¯ã¿ãŒãšããŠãããã€ãã»ã°ããŒãã«ã»ã»ã³ã¿ãŒã»ãã©ãŒã»ã¬ã®ã¥ã©ããªãŒã»ãšã¯ã»ã¬ã³ã¹ã»ãã©ãŒã»ã©ã€ããµã€ãšã³ã¹ãçãã欧å·å»è¬ååºãšãã®ããã°ã©ã ã«ããã€ããµãŒãã¹ã®ã¬ããã³ã¹ãæäŸããŠããŸãããããã€ãå ¥ç€Ÿåã¯ãç 究éçºååŠè ãšããŠæŽ»èºããŠããŸãããååŠãšçµå¶ç§åŠã®çåŠå£«å·ãšååŠã®ä¿®å£«å·ãååŸã
Tracy Wu ã¯ãAPeJ å°åã®ã¡ãã£ããŒã¿ã°ããŒãã«ã³ã³ãã©ã€ã¢ã³ã¹ã»æŠç¥ããŒã ã®ã·ãã¢ãªãŒããŒã§ãèŠå¶å¯Ÿè±¡äŒæ¥ã«ãµãŒãã¹ãæäŸãã SaaS ãã¯ãããžãŒäŒæ¥ãšããŠã®ã¡ãã£ããŒã¿ã®é¢å¿ãèŠå¶åœå±ã®èªèã«åæ ããããããçŸå°ã®èŠå¶åœå±ãšã®é£æºã«æ³šåããGxP é¢é£ã®èŠå¶å€æŽãšã¡ãã£ããŒã¿ã®åå°åã«ãããäºæ¥ãžã®åœ±é¿ãè©äŸ¡ããŠããŸãããŸãã顧客ãšçŽæ¥å¯Ÿè©±ããèšåºè©Šéšã®å®æœã«ãããæè¡ã®äœ¿çšã«é¢é£ããå質ããã³èŠå¶é¢é£äºé ã«å¯Ÿå¿ããŠããŸããã¡ãã£ããŒã¿ã«å ¥ç€Ÿããåã¯ãã°ããŒãã«è£œè¬äŒæ¥ã§å質ä¿èšŒç£æ»äººãšããŠGXPç£æ»ã®å®æœãæ åœããŠããŸããããŸããäžåœã®ãã€ãªãã¯ãããžãŒäŒæ¥ã§ç 究éçºå質ä¿èšŒã®è²¬ä»»è ãšããŠèšåºéçºå質管çã·ã¹ãã ã確ç«ãã瀟å ã®å質é¢é£äºé å šè¬ãç£ç£ããŠããŸããã
Sastry Chilukuriã¯ãããžã¿ã«ããã³AIãœãªã¥ãŒã·ã§ã³æ åœã®ãšã°ãŒã¯ãã£ãã»ãã€ã¹ãã¬ãžãã³ããšããŠãã©ã€ããµã€ãšã³ã¹é¡§å®¢ã®ã€ãããŒã·ã§ã³ã®å éãæ¯æŽããæ©èœã®éçºãåžå Žæå ¥ãæäŸã®å éãæ åœããŠããŸããSastryã¯ãã«ã¹ã±ã¢æè¡ã®åéã§19幎ã®çµéšãæã£ãŠããŸããçŽè¿ã§ã¯McKinsey & Companyã®ããŒãããŒãšããŠã12幎éãäžçäžã®ãã€ãªãã¡ãŒããå»çæ©åšããã¯ãããžãŒãå ¬å ±éšéãèŠå¶åœå±ã®ã¯ã©ã€ã¢ã³ãã«ã¢ããã€ã¹ãæäŸããŠããŸããããã以åã¯ãGEãã«ã¹ã±ã¢ã§ãœãããŠã§ã¢ãšã³ãžãã¢ãªã³ã°ã補åéçºããªãã¬ãŒã·ã§ã³ã«åŸäºããŠããŸããã圌ã®èŠè§£ã¯ãã«ã³ãã¡ã¬ã³ã¹ãã¡ãã£ã¢ãMcKinsey Insightsã§ã®å€æ°ã®åºçç©ãªã©ãåºãç¥ãããŠããŸããããŒã¹ãŠã§ã¹ã¿ã³å€§åŠã±ããã°çµå¶å€§åŠé¢ã§çµå¶åŠä¿®å£«å·ããªãã€ãªå·ç«å€§åŠã§çåŠä¿®å£«å·ãã€ã³ãã®ãã©ãã·ã«ããã€ã³ãå·¥ç§å€§åŠïŒBHUïŒã§æè¡åŠå£«å·ïŒB.TechïŒãååŸã
Arnaub Chatterjee ã¯ãã¡ãã£ããŒã¿ã®ãœãªã¥ãŒã·ã§ã³äŒæ¥ Acorn AI ã®è£œåã»ãšã³ã·ã¹ãã æ åœã·ãã¢ãã€ã¹ãã¬ãžãã³ãã§ããã¡ãã£ããŒã¿ã¯ã©ã€ããµã€ãšã³ã¹åéã«ãããã¯ã©ãŠãããŒã¹ããã³åæãœãªã¥ãŒã·ã§ã³ã®ã°ããŒãã«ãããã€ãã§ãåæ°ã®åœ¹å²ã¯ãã©ã€ããµã€ãšã³ã¹åéã®é¡§å®¢ãã€ãããŒã·ã§ã³ãå éãããã®ãæ¯æŽããæ©èœã®éçºãåžå Žæå ¥ãæäŸã«é¢ããåãçµã¿ãæšé²ããããšã§ãããŸããããŒããŒãã»ã¡ãã£ã«ã«ã»ã¹ã¯ãŒã«ã®ãã«ã¹ã±ã¢æ¿çåŠç§ã®ãã£ãŒãã³ã°ã»ã¢ãœã·ãšã€ããã³ãŒãã«å€§åŠã®æ¿çåæã»çµå¶åŠç§ã®è¬åž«ãåããŠããŸãã
ãããŒã®ç 究çµéšã¯20幎ã«åã³ãèšåºéçºã®ãããã段éãšè£œåã¿ã€ãã®è€æ°ã®æ²»çåéã«ããã£ãŠããŸãããã®äžã«ã¯ãå»è¬åãçç©åŠç補å€ãå»çæ©åšããã现èã»çµç¹è£œå€ïŒHCT/PsïŒãªã©ãå«ãŸããŸããã°ããŒãã«ãªèšåºããŒã ãè©Šéšã®ç®¡çã»ç£ç£ãè¡ãã倧æCROãæ©èœæ§ãµãŒãã¹ãããã€ããŒã倧èŠæš¡ã»å°èŠæš¡ã®ãã€ãªããã¯ãå»çæ©åšãçµç¹å ã®èšåºæ¥åã§è€æ°ã®åœ¹å²ãæ ã£ãŠããŸããã ãžã§ãŒãžã»ã¯ã·ã³ãã³å€§åŠå»åŠéšãšã¿ãã倧åŠã§èšåºç 究ã«çŠç¹ãåœãŠã倧åŠé¢åŸã®ãã¬ãŒãã³ã°ãä¿®äºããèšåºç 究管çãè¬çåŠãå»è¬åéçºãšèŠå¶ãå»è¬åéçºããŒã ã®ãªãŒããŒã·ãããåŠã³ãèšåºç 究å°é家åäŒïŒAssociation of Clinical Research ProfessionalsïŒã®èšåºç 究å°é家ãšããŠã®è³æ Œãä¿æããŠããŸããTissueTechã®èšåºæ¥åæ åœå¯ç€Ÿé·ãšããŠããããŒã¯ãèšåºãã¶ã€ã³ãç®çãéæããããã«æãæé©ãªæ¹æ³ã§å®æœãããããã«ãå瀟ã®è³ç£ã®èšåºè©Šéšãããã³ã«ãã¿ã€ã ã©ã€ã³ãäºç®ã®éçºã«æŠç¥çãªãªãŒããŒã·ãããšã€ã³ããããæäŸããå®å šãªèšåºæ¥åéšéãšã€ã³ãã©ã¹ãã©ã¯ãã£ã®æ§ç¯ãæ¯æŽããŠããŸããã 2017幎11æãFDAã¯ãæ£è ãžã®HCT/Pã®ããå®å šã§å¹æçãªããªããªãŒã確å®ã«ããããã®åãçµã¿ãšããŠããã现èã»çµç¹ããŒã¹è£œåïŒHCT/PïŒæ¥çã«å¯ŸããŠæ°ããªã¬ã€ãã³ã¹ãçºè¡šããŸããããã®çµæãTissueTechã¯ãæ ¢æ§åµå·ãçéªšæ Œç³»çŸæ£ãåžå°çŸæ£ã®æ²»çãçŒè¡šé¢æ©èœã®å埩ãªã©ã®ã¢ã³ã¡ããã»ã¡ãã£ã«ã«ã»ããŒãºã«çŠç¹ãåœãŠãäžé£ã®æ²»éšçšæ°è¬èšåºè©Šéšãå«ããå³æ Œãªçç©è£œå€ã©ã€ã»ã³ã¹ç³è«ããã»ã¹ãå®æœããŠããŸãããããã®å€æ®µéèšåºè©Šéšã¯ãMSHSã®èšåºæ¥åæ åœå¯ç€Ÿé·ã§ããTommy Leeæ°ã®ç£ç£ã®ããšãç±³åœå ã®è€æ°ã®å Žæã§å®æœãããŠããŸãã
ãã€ã±ã«ã¯ã¡ãã£ããŒã¿ã®ã¢ãã€ã«ãã«ã¹ããŒã ã®ã¡ã³ããŒã§ãé»åçã€ã³ãã©ãŒã ãã³ã³ã»ã³ããšä»®æ³è©Šéšã®å°é家ã§ãã éå»6幎éãäžçäžã®ã¹ãã³ãµãŒãCROãèŠå¶åœå±ãå«çå§å¡äŒãç 究è ãšååããŠãé»åçã€ã³ãã©ãŒã ãã³ã³ã»ã³ããšä»®æ³è©Šéšã®å©çšãéæããŠããŸããã å»åŠç 究ã«ããã30幎ã®ãã£ãªã¢ã®äžã«ã¯ãç±³åœæ¿åºã§8幎éå€ç§ç 究ãå®æœã»æ¯æŽããåæ¥éšéã§22幎éåããåèšåºããã³èšåºç 究ãæ¹åã»æ¯æŽããæè¡ãœãªã¥ãŒã·ã§ã³ãæäŸããŠããçµéšãå«ãŸããŸãã ãã€ã±ã«ã¯2ã€ã®èšåºè©Šéšã«åå ããŸããããeConsentããŸã çºæãããŠããªãã£ããããçŽã®äžã§åæããªããã°ãªããŸããã§ããããã€ã±ã«ã¯ç±³åœæµ·è»ã®é圹è»äººã§ããããããµã¹å·ãªãŒã¹ãã£ã³ã«åšäœããéžæã§éžã°ããå ¬åå¡ãšããŠå°å瀟äŒã«å¥ä»ããŠããŸãã
ãã£ã¢ã·ãŒã»ãã§ã³ã¯ãã¡ãã£ããŒã¿ã»ãœãªã¥ãŒã·ã§ã³ãºã®ã¢ãã€ã«ãã«ã¹æ åœãã£ã¬ã¯ã¿ãŒãšããŠãã¢ãã€ã«ã»ã³ãµãŒãšã¢ããªãèšåºè©Šéšã«çµ±åãããœãªã¥ãŒã·ã§ã³ãéçºããŠãããç±³åœã欧å·ãã¢ãžã¢ã§ã®å°å ¥çµéšããããŸããClinical Trials Transformation Initiative ã® Novel Endpoints ãããžã§ã¯ãã®ã¡ã³ããŒã§ãã¹ãã³ãµãŒãåŠè¡æ©é¢ãæ¥çå£äœãèŠå¶åœå±ãšååããŠãã¢ãã€ã«ã»ã³ãµãŒããŒã¿ã®å©çšã«ãããã€ãããŒã·ã§ã³ãæšé²ããŠããŸããã¡ãã£ããŒã¿ã«å ¥ç€Ÿããåã¯ããã©ã€ã¹ãŠã©ãŒã¿ãŒããŠã¹ã¯ãŒããŒã¹ã®æè¡ã³ã³ãµã«ã¿ã³ããåããã¯ã€ã«ã³ãŒãã«å€§åŠå»åŠéšã§æ å ±æ¿ç管çãæ åœããŠããŸãããã«ãŒãã®ãŒã¡ãã³å€§åŠã§æ å ±ã·ã¹ãã 管çã®åŠå£«å·ãšä¿®å£«å·ãååŸããŠããŸãã
ãã ã¯ãå»è¬åã®ããªã¥ãŒãã§ãŒã³ã«ãããŠ18幎以äžã®çµéšãæã€ããã¯ãããžãŒãšã€ãããŒã·ã§ã³ã®ãªãŒããŒãšããŠç¥ãããŠããŸããèšåºéçºãå éããããµãã©ã€ãã§ãŒã³ãæé©åããæ°èŠæ²»çæ³ãå¹æçã«åžå Žã«æå ¥ããããã«ããã¯ãããžãŒãšã©ã€ããµã€ãšã³ã¹ã®äº€å·®ç¹ã«æ³šåããŠããŸããããŒã¿ãã¡ããªãã¯æ åœã·ãã¢ãã€ã¹ãã¬ãžãã³ããšããŠãã¡ãã£ããŒã¿ã®ããŒã¿ãã¡ããªãã¯ããžã§ã³ãšãäžçã§æãè±å¯ãªçµ±åã»æšæºåãããèšåºããŒã¿ã»ããã代衚ããMEDSãã©ãããã©ãŒã ãçããŠããŸãã2019幎ã«ã¡ãã£ããŒã¿ã«å ¥ç€ŸããŠä»¥æ¥ãTomã¯ããŒã¿ãã¡ããªãã¯ãšæ©æ¢°åŠç¿ïŒMLïŒãèªç¶èšèªåŠçïŒNLPïŒãã»ãã³ãã£ã¯ã¹ãå«ãAIããŒã¹ã®ãã¯ãããžãŒã®æŽ»çšãæšé²ããã¹ãã³ãµãŒãCROåãã«æ¥çããªãŒããã補åãšåæãæšé²ããæŠç¥çãã©ãããã©ãŒã ãæ§ç¯ããŠããŸãããã¡ãã£ããŒã¿ã«å ¥ç€Ÿããåã¯ãäžçæ倧çŽã®ã©ã€ããµã€ãšã³ã¹äŒæ¥ã§ããŒã¿ãµã€ãšã³ã¹æ¥åãçããŠããŸãããèšåºè©Šéšã®å®æœå¯èœæ§ãçŸç äºæž¬ãå¶æ¥ããŒã ã®æå¹æ§ãæ£è ã®æç¶æ§ãªã©ã®åéã§ãæå 端ã®MLããã³NLPããŒã¹ã®ãœãªã¥ãŒã·ã§ã³ã®æ¢çŽ¢ãšéçºãäž»å°ããŸããããŸãã倧æ補è¬äŒç€Ÿã®ç 究éçºãåæ¥ããµãã©ã€ãã§ãŒã³ã«ãããŠããã¯ãããžãŒãšã¢ããªãã£ã¯ã¹ã®ãªãŒããŒç圹å²ãæ ã£ãŠããŸããããŠã©ãŒã¿ãŒã«ãŒå€§åŠã§æ°åŠãšã³ã³ãã¥ãŒã¿ãµã€ãšã³ã¹ã®åŠäœãååŸããã©ã€ããµã€ãšã³ã¹åéã®ãã¯ãããžãŒã«ãã£ãªã¢ãéäžãããŠããŸãã
ãã£ã ã¯ãã¡ãã£ããŒã¿ã® eTMFããµã€ãã¯ã©ãŠããå«ã RCM ãã©ãããã©ãŒã ã®ãããã¯ããã£ã¬ã¯ã¿ãŒã§ããç 究çµäºãã¢ãŒã«ã€ããå質管çãªã©ãå«ãŸããŸããSOP管çãå«ãRCMãã©ãããã©ãŒã ã®ãããã¯ããã£ã¬ã¯ã¿ãŒãåããŠããŸããã¡ãã£ããŒã¿ã«å ¥ç€ŸããŠãããèšåºç 究ã§16幎以äžã®çµéšãç©ãã§ããŸããèšåºãã£ãªã¢ã®å€§åããæ²»éšè¬ç®¡çãTMFãµãŒãã¹ããœãããŠã§ã¢å®è£ ããããžã§ã¯ã管çã«è²»ãããŠããŸãããPPDãRPSãPRAHSãTransperfect ã«å€åããçµéšããããŸãã圌ã®åœ¹å²ã¯ã瀟å ã®CRAãµããŒããTMF管çãè©Šéšéå§ãå®çŸå¯èœæ§ãç£ç£ããŠããŸããããæè¿ã§ã¯ãTransPerfectã®eClinical補åã®Trial Interactiveã¹ã€ãŒãã®èšåºãªãã¬ãŒã·ã§ã³ã®ãã£ã¬ã¯ã¿ãŒãåããŠããŸããTransPerfect 瀟ã§ã®çŽè¿ã®è·åã¯ããããžã§ã¯ã管çãTMF ç£æ»æºåãå®è£ /èšå®ãTMF ææžã¬ãã¥ãŒåŠçã«ç¹åããç£ç£ãè¡ãã顧客ã«æäŸããèšåºãµãŒãã¹ãæåãããããšã«éç¹ã眮ããŠããŸããããã£ã ã®ã¡ãã£ããŒã¿ã§ã®åœ¹å²ã¯ãeTMFããµã€ãã¯ã©ãŠãã®äœ¿çšã«é¢ãã顧客ã®ãµããŒããšã³ã³ãµã«ãã£ã³ã°ããå§ãŸããŸãããæ²»éšçµäºãCTMSãæ²»éšè²¬ä»»å»åž«ãžã®æ¯æããã°ã©ã³ããããŒãžã£ãŒã®ãµããŒããšã³ã³ãµã«ãã£ã³ã°ãéå§ããŸããã
Pat Pollard ã¯ãã¡ãã£ããŒã¿ã®é¡§å®¢ãµãŒãã¹æ åœããªã³ã·ãã«ã§ãRave eTMFãã¢ãŒã«ã€ãããµã€ãã¯ã©ãŠãã®è©ŠéšçµäºåŸã®å®è£ ãæ åœãããããžã§ã¯ããããŒãžã£ãšå®è£ ã³ã³ãµã«ã¿ã³ããããªããããã§ãã·ã§ãã«ãµãŒãã¹ããŒã ãçããŠããŸããã©ã€ããµã€ãšã³ã¹åéã§20幎ã®çµéšãæã¡ãç 究ã»èšåºéçºã¢ããªã±ãŒã·ã§ã³ã®å°å ¥ã»ãµããŒãããŒã ã®ç®¡çã«æºãããGxPææžç®¡ç (eTMFãèŠå¶åœå±ãžã®æåºãšå質管ç) ã®å®å šæ§ãšèšåºæ€æ»ã¢ããªã±ãŒã·ã§ã³ãªã©ãæ åœããŠããŸããã ãŸãã補åã®è²·åã売åŽã®äžç°ãšããŠãèŠå¶ææžã¢ããªã±ãŒã·ã§ã³ã®éçºãå®è£ ãã³ã³ãã³ãã®ç§»è¡ã管çããŠããè±å¯ãªå°éç¥èãæããŠããŸããã¡ãã£ããŒã¿ã«å ¥ç€Ÿããåã¯ãChita Inc ãš Daybreak Information Technologies ã®åµç«ã¡ã³ããŒã§ããã 2002幎ãã2013幎ãŸã§ãšã©ã³è£œè¬ã§ç 究éçºã¢ããªã±ãŒã·ã§ã³æ åœãã€ã¹ãã¬ãžãã³ããåããŸããããœãããŠã§ã¢ãšã³ãžãã¢ãšããŠåå°äœæ¥çã§ãã£ãªã¢ãã¹ã¿ãŒããããã¢ãã€ã«éä¿¡ãéè¡ã§ãäžçŽæè¡è·ãåããŸããã
ãã«ããŒã«ã»ã·ã£ã«ã¬æ°ã¯ã1995幎ãããããœãŒã»ã·ã¹ãã ãºã®CEOãåãã2016幎ããã¯åç· åœ¹äŒã®å¯äŒé·ãåããŠããŸãã1983幎ã«æ°èšèšæè¡ã®éçºã®ããã«å ¥ç€Ÿãããã£ãªã¢ãã¹ã¿ãŒããããŸããã1986幎ã«ã¯æ°æè¡ã»ç 究ã»æŠç¥ã®å°ééšçœ²ãèšç«ãã1988幎ã«ã¯æŠç¥ã»ç 究ã»éçºéšéã®ç€Ÿé·ã«å°±ä»»ããŸãããã·ã£ã«ã¬ã¹ã¯ããããœãŒã»ã·ã¹ãã ãºã®ç§åŠçèœåãããã«åŒ·åããç§åŠãäŒç€Ÿã®DNAã®äžéšã«ããããã«ãç¶ç¶çãªã€ãããŒã·ã§ã³ã®æåã浞éãããã®ã«è²¢ç®ããŸãããããžã¿ã«ã»ã¢ãã¯ã¢ããã補åã©ã€ããµã€ã¯ã«ç®¡çã3DEXPERIENCE®ã®èåŸã«ããã€ã³ã¹ãã¬ãŒã·ã§ã³ã¯ã3Dæè¡ã¯äžå¯èœãå¯èœã«ãããã®ã§ãããšç¢ºä¿¡ããŠããŸãã3DãŠãããŒã¹ã¯ãã³ã³ã»ããããã¹ãããæªæ¥ãåµé ããããã®æã匷åãªæ段ã§ããã倢ãšçŸå®ãçµã³ã€ããç§åŠãšæ³ååã®éçãè¶ ããŠç€ŸäŒã®é²æ©ãä¿é²ããŸããã·ã£ã«ã«ã¯ããããœãŒã»ã·ã¹ãã ãºãã€ãããŒã·ã§ã³ã®ããã®å¥œãŸããããŒãããŒãšããŠäœçœ®ã¥ãã競äºåã®ããããã©ãŒãã³ã¹ãæç¶çã«å€åãããããšã§ãããžãã¹ã«åãäžããŠããŸãã1981幎ã«èšç«ããã3DãœãããŠã§ã¢ã®äžççãªãŒããŒã§ããå瀟ã¯ãã³ãŒãã¬ãŒãã»ãã€ãèªã®ãäžçã§æãæç¶å¯èœãªäŒæ¥ãã«éžã°ãããã©ãŒãã¹èªã®ãäžçã§æãé©æ°çãªäŒæ¥ãã«ãéžã°ããŠããŸããBernard CharlÚsã¯ããµããã£ã®åç· åœ¹äŒã®ã¡ã³ããŒã§ããç±³åœåœç«å·¥åŠã¢ã«ãããŒã®å€åœäººäŒå¡ã§ããããã©ã³ã¹æè¡ã¢ã«ãããŒã®äŒå¡ã§ããããŸãã圌ã¯ãLégion d’honneurãïŒãã©ã³ã¹åèªè»å£ïŒã®å£«å®ã®éçŽãä¿æããŠããŸããã«ã·ã£ã³ã®ãšã³ãŒã«ã»ãã«ãã«ã»ã·ã¥ããªãŠãŒã«å·¥ç§åŠæ ¡ãåæ¥ããæ©æ¢°å·¥åŠã®å士å·ïŒèªååå·¥åŠãšæ å ±ç§åŠãå°æ»ïŒãååŸããŠããŸãããŸãããã©ã³ã¹ã§æãäžçŽã®æè·è³æ Œã§ããã¢ã°ã¬ã¬ã·ãªã³ïŒæ©æ¢°å·¥åŠãå°éãšããïŒãååŸããŠããŸãã
ãããœãŒã»ã·ã¹ãã ãºã®ã©ã€ããµã€ãšã³ã¹ç£æ¥æ åœãã€ã¹ãã¬ãžãã³ããšããŠã3DEXPERIENCEãã©ãããã©ãŒã ã掻çšããŠæ¬¡äžä»£ã®æ²»çæ³ã觊åªããããšã§ãäŒæ¥ã®ç§åŠçã€ãããŒã·ã§ã³ãžã®ã¢ãããŒããããžã¿ã«åããæ¯æŽãæ åœããŠããŸãããã以åã¯ããã€ãªè£œè¬äŒç€ŸLFBã§å·¥æ¥çšã¡ãœããã®ãããŒãžã£ãŒãåããåŸããã©ã³ã¹ä¿å¥çã§å¥åº·é£åã®äŸ¡æ Œèšå®ãšåéã®éšéé·ãåããŠããŸããã æè¿ã§ã¯ãAgence Générale des Ãquipements et Produits de Santé (AGEPS) ã®ãããŒãžã³ã°ãã£ã¬ã¯ã¿ãŒãåããŸããããã©ã³ã¹ã® Ecole Polytechnique ããã³ Corps des Mines ããã°ã©ã ã§å·¥åŠã®åŠäœãååŸããã»ãããã¥ãŒãšãŒã¯ã® Watson School of Biological Sciences ã§çåœç§åŠã®ä¿®å£«å·ããInstitut Pasteur ã§å ç«åŠã®å士å·ãååŸããŠããŸãããŸããäžçä¿å¥æ©é¢ïŒWHOïŒã®ããã€ãã®ã¯ãŒãã³ã°ã°ã«ãŒãã®ã¡ã³ããŒãšããŠã掻èºããŠããŸãã
Tarek ã¯ããããœãŒã»ã·ã¹ãã ãºã®ã¡ãã£ããŒã¿ç€Ÿã®å ±åæé«çµå¶è²¬ä»»è ïŒCEOïŒå Œå ±ååµæ¥è ã§ããã¡ãã£ããŒã¿ãæ°èäŒæ¥ããã©ã€ããµã€ãšã³ã¹æ¥çåãã¯ã©ãŠãããŒã¹ã®ãœãªã¥ãŒã·ã§ã³ãæäŸãããªãŒãã£ã³ã°ã»ã°ããŒãã«ã»ãããã€ãã«æé·ããããã¥ãŒãšãŒã¯åžã§èšç«ããããã¯ãããžãŒäŒæ¥ãšããŠã¯æ倧çŽã®èŠæš¡ãèªããŸããã¡ãã£ããŒã¿ã¯èšåºè©ŠéšããŒã¿ã®åéã»ç®¡çã«ãããã°ããŒãã«ãªãŒããŒã§ããã120ã«åœä»¥äžã§èšåºè©ŠéšããµããŒãããäžæ¹ãåçŽåã¯ã©ãŠãäŒæ¥ã®ããžãã¹ã¢ãã«ãå®çŸ©ããŠããŸããã¿ã¬ãã¯ã¯2020幎ããããœãŒã»ã·ã¹ãã ãºã®ã©ã€ããµã€ãšã³ã¹ã»ãã«ã¹ã±ã¢éšéã®äŒé·ã«å°±ä»»ããŸãããTarek ã¯ãå»çæè¡ãšéèã®åé㧠30 幎以äžã®ãªãŒããŒã·ããçµéšãæã£ãŠããŸããã¡ãã£ããŒã¿ã«å ¥ç€Ÿããåã¯ãå ¬éã»éå ¬éæè¡ã»ã©ã€ããµã€ãšã³ã¹äŒæ¥ã察象ãšãããšã¯ã€ãã£ãã¡ã³ãã®å ±åçµå¶ã»ç®¡çãè¡ããšãšãã«ãéèåéã§ããŸããŸãªåœ¹è·ãæŽä»»ããŸããã1984幎ã«ãšãŒã«å€§åŠã§çµæžåŠã®æåŠå£«å·ãååŸãã1991幎ã«ã³ãã³ãã¢ã»ããžãã¹ã»ã¹ã¯ãŒã«ãåæ¥ããçµå¶åŠãšè²¡åã®åŠäœãååŸããŸããããã¥ãŒãšãŒã¯åžæ°ã®ããã®ããžãã¹æ©äŒãšéçšã®åµåºã«åãå ¥ããŠãããã¥ãŒãšãŒã¯åžããŒãããŒã·ããåºéã®å ±åè°é·ãåããŠããŸããã¿ã¬ãã¯ã¯ãŸãã極å°ãžã®æè²çé åŸãéããéå°å¹Žã®åºæ¿ã«çŠç¹ãåœãŠãéå¶å©å£äœãStudents on Iceãã®è«®åå§å¡äŒãããã¥ãŒãšãŒã¯å€§åŠã©ã³ãŽãŒã³å»çã»ã³ã¿ãŒã®çéªšæ Œç³»è«®åå§å¡äŒã®å§å¡ãåããŠããŸãã
ãžã§ã·ã¥ã¢ã¯ãSyneos Health ã®ãã€ãªã¡ããªã¯ã¹äºæ¥éšã®æŠç¥çæè¡æšé²ããŒã ãçããŠããŸãã 圌ã¯é©æ°çã§é«åºŠãªãã¯ãããžãŒã®äœ¿çšãæšé²ããã¹ãã³ãµãŒããªãã¬ãŒã·ã§ã³ããŒã ããã¯ãããžãŒãããã€ããŒãšååããŠãèšåºéçºãä¿é²ããããã«ç®çã«åã£ãã¿ãŒã²ãããçµã£ããœãªã¥ãŒã·ã§ã³ãæäŸããŠããŸãã 20幎ã«åã¶èšåºç 究ã®çµéšã®äžã§ãããŒã¿éçšããã³æè¡å®è£ ããŒã ãçããå¹ åºãã¹ãã³ãµãŒãæ¥çããªãŒããããã¯ãããžãŒãããã€ããŒãšå¯æ¥ã«ååããŠããŸããã ç 究ãšäžçã®å¥åº·ãåé²ãããããã«ãæ£è ããããã€ããŒã®è² æ ã軜æžããæè¡ãå®è£ ããå¿ èŠæ§ã«æ ç±ã泚ãã§ããŸãã SCDM ã®ã€ãããŒã·ã§ã³å§å¡äŒã Medidata NEXT ã«ç©æ¥µçã«åå ããè²¢ç®ããŠããŸãã
ãŽã¡ã¬ãªãŒã»ãšã¹ãã¹ã¯ãå§åŠ¹ã®ãžã§ããã¡ãŒãã¡ã¬ãã£ã¹ãšå ±ã«ããžã§ããã¡ãŒã35æ³ã®æã«çèçž®æ§åŽçŽ¢ç¡¬åçïŒALSïŒãšèšºæãããåŸã1998幎ã«ãããžã§ã¯ãALSãèšç«ããŸããã22幎éã§ããããžã§ã¯ãALSã¯ALSç 究ã®ããã«1åãã«ä»¥äžã®è³éãéããç§åŠãšå»åŠãç æ°ã®ç 究ã«åãçµãæ¹æ³ã«é©åœãèµ·ãããŸããããŽã¡ã¬ãªãŒã¯ç 究責任è ãšããŠãäžçããªãŒãããç§åŠè ãèšåºå»ïŒãã®å€ãã¯ç«¶äºçžæã§ããïŒã«ãALSãã¢ã«ããã€ããŒç ãããŒãã³ãœã³ç ããã³ãã³ãã³ç ãªã©ã®ç¥çµå€æ§çŸæ£ãšå¯æ¥ã«é¢é£ããALSã®ç解ãæ·±ããããã«ãç©æ¥µçãã€ççŽã«ããããŠååããŠç 究ã«åãçµãæ欲ãæãããŠããŸãããžã§ããã¡ãŒãšå ±ã«ããŽã¡ã¬ãªãŒã¯å šç±³ãã¹ãã»ã©ãŒãTales from the Bedãã®èè ã§ããããŸãã圌女ã¯TodayãCharlie RoseãLarry King LiveãEntertainment TonightãNBCãMSNBCã«åºæŒããçŸåšé²è¡äžã®ALSãããžã§ã¯ãã®ã¹ããŒãªãŒã¯ãã¥ãŒãšãŒã¯ã¿ã€ã ãºãããŒãã«ãã°ããããŠã¹ããŒãã³ã°ããã©ãŒãã¹ããã©ãŒãã¥ã³ãªã©ã®éèªã«ãåãäžããããŠããŸããALSãããžã§ã¯ãã®ã¹ããŒãªãŒã¯ãHBOã®ãªãªãžãã«ããã¥ã¡ã³ã¿ãªãŒãThree Sisters. ã¢ã«ãããŒè³ãåè³ããã·ãŒã©ã»ããã³ãºãå¶äœãããã¹ãªãŒã·ã¹ã¿ãŒãºïŒæ²»çæ³ãæ¢ããŠãã¯ãé«ãè©äŸ¡ãåŸãŠããŸãã
ãšãªã³ã»ãã¬ãã³ã°ã¯ãã³ãã³ãã¢å€§åŠã®Project ALS Therapeutics Core (THE CORE)ã®å€éšãªãã¬ãŒã·ã§ã³æ åœãã£ã¬ã¯ã¿ãŒãåããŠããŸããTHE COREã¯ãALSæ²»çè¬ã®éçºãåèšåºè©äŸ¡ãèšåºè©Šéšã«å šé¢çã«åãçµãã§ããäžçææ°ã®éå¶å©å£äœãšäžçææ°ã®åŠè¡æ©é¢ãšã®éã®äžçåã§å¯äžã®ããŒãããŒã·ããã§ãããã以åã¯ãProject ALSã®ã¢ãœã·ãšã€ããã£ã¬ã¯ã¿ãŒãApplied Therapeuticsã®ãããžã§ã¯ããããŒãžã£ãŒãããã£ãã¯åã©ã€ããµã€ãšã³ã¹ã³ã³ãµã«ãã£ã³ã°äŒç€ŸClearpoint Strategy Groupã®ãããžã§ã¯ããã£ã¬ã¯ã¿ãŒãåããŠããŸãããã³ãã³ãã¢å€§åŠã§è±èªãšæ¯èŒæåŠã®æåŠå£«å·ãååŸããŠããŸãã
ã·ãŒã©ã»ãã€ã¢ã¢ã³ã (MS, CGC) ã¯ãã¡ãã£ããŒã¿ã®äŒæ¥ã§ãã Acorn AI ã§ç§åŠçäºæ¥éçºãå®æœããã¡ãã£ããŒã¿ã»ã€ã³ã¹ãã£ãã¥ãŒããçããŠããŸããããŒã¿ãšæè¡ã®é²æ©ã粟å¯å»çãšæ£è ã±ã¢ã«ç確ã«çµ±åããããã«ãæèã®ãªãŒããŒã·ãããçºæ®ããã©ã€ããµã€ãšã³ã¹ããŒãããŒãšã®é¢ä¿ãæ§ç¯ããŠããŸããã·ã§ã€ã©æ°ã¯ãç¥çµå€æ§çŸæ£ã®éºäŒçãªã¹ã¯ãã€ãªããŒã«ãŒã®è§£éãšé瀺ãããã³çŽ å æ§å šã²ãã ã·ãŒã¯ãšã³ã·ã³ã°ãå°éãšãããçäºäŒèªå®ã®éºäŒã«ãŠã³ã»ã©ãŒã§ããã¡ãã£ããŒã¿å ¥ç€Ÿä»¥åã¯ãããªã¬ã ã»ã¢ã³ãã»ãŠã£ã¡ã³ãºç é¢ãšããŒããŒãã»ã¡ãã£ã«ã«ã»ã¹ã¯ãŒã«ã®Genomes2Peopleç 究ããã°ã©ã ã«å€åããã²ãã æ å ±ãå»çã瀟äŒã§å©çšããããšã«ããå»åŠçãè¡åçãçµæžç圱é¿ã«é¢ããå®èšŒç 究ãè¡ã£ãŠããŸãããç±³åœéºäŒã«ãŠã³ã»ãªã³ã°å§å¡äŒïŒABGCïŒã®ãã£ããã¡ã€ãã§ãããå šç±³éºäŒã«ãŠã³ã»ã©ãŒåäŒïŒNSGCïŒã®ã¡ã³ããŒã§ããã»ãã粟å¯å»åŠããã³ç£æ¥çã®ç¹å¥å©çã°ã«ãŒãã®ã¡ã³ããŒã§ããããŸãããã¹ãã³å€§åŠå»åŠéšã§éºäŒã«ãŠã³ã»ãªã³ã°ã®ç§åŠä¿®å£«å·ãååŸã
æºåäž
æºåäž
ãšã³ã¿ãŒãã©ã€ãºåããœãããŠã§ã¢ã®éçºããããžã§ã¯ããããŒãžã£ãŒãäŒç»ã»ã¯ã·ã§ã³ãçµãŠã2011幎ã¡ãã£ããŒã¿ã»ãœãªã¥ãŒã·ã§ã³ãºæ ªåŒäŒç€Ÿã«å ¥ç€Ÿã以éããœãªã¥ãŒã·ã§ã³ã³ã³ãµã«ã¿ã³ããšããŠã顧客ã«æ§ã ãªè£œåã»ãµãŒãã¹ã®ãã¢ã³ã¹ãã¬ãŒã·ã§ã³ãè¡ããªããã顧客ãæã€èª²é¡ã«å¯Ÿãã解決æ¹æ³ãææ¡ããŠããã
æºåäž
å€è³ç³»è£œè¬äŒæ¥ãCROã«ãããã¢ãã¿ãªã³ã°æ¥åãã¡ãã£ã«ã«ã©ã€ãã£ã³ã°æ¥åçãçµãŠã2005幎ã«ã¡ãã£ããŒã¿ã»ãœãªã¥ãŒã·ã§ã³ãºæ ªåŒäŒç€Ÿã«ç«ã¡äžãã¡ã³ããŒãšããŠåç»ãæ¥æ¬ã§æåã®RaveïŒEDCïŒå°å ¥ãããžã§ã¯ãã«ãããžã§ã¯ããããžã£ãŒãšããŠæºããã2008幎-2012幎ãã¥ãŒãšãŒã¯æ¬ç€Ÿå€åãAPACåã補åããŒã«ãªãŒãŒã·ã§ã³ããªãŒãåŸãçŸåšã¯ã·ãã¢ã»ãœãªã¥ãŒã·ã§ã³ã³ã³ãµã«ã¿ã³ãããã³ãUSæ¬ç€Ÿã®çªå£ãšããŠeConsentãeCOAçã®ã¢ãã€ã«ãã«ã¹ããŒã«ãäžå¿ã«æ¥æ¬ã®èšåºè©Šéšã«æ®åããPatient Centricityããã¯ãããžãŒåŽããå®çŸãã¹ã掻åäžã
ãšã³ã¿ãŒãã©ã€ãºåããœãããŠã§ã¢ã®éçºããããžã§ã¯ããããŒãžã£ãŒãäŒç»ã»ã¯ã·ã§ã³ãçµãŠã2011幎ã¡ãã£ããŒã¿ã»ãœãªã¥ãŒã·ã§ã³ãºæ ªåŒäŒç€Ÿã«å ¥ç€Ÿã以éããœãªã¥ãŒã·ã§ã³ã³ã³ãµã«ã¿ã³ããšããŠã顧客ã«æ§ã ãªè£œåã»ãµãŒãã¹ã®ãã¢ã³ã¹ãã¬ãŒã·ã§ã³ãè¡ããªããã顧客ãæã€èª²é¡ã«å¯Ÿãã解決æ¹æ³ãææ¡ããŠããã
Rosamund Roundã¯ãã¬ã¯ã»ã«ã®æ£è ã€ãããŒã·ã§ã³ã»ã³ã¿ãŒã®å¯ç€Ÿé·ã§ãã圌女ã¯èšåºç 究ãžã®ã¢ã¯ã»ã¹ãšçµéšã®åäžã«å°œåããŠãããåæ£åèšåºè©ŠéšãµãŒãã¹ãåµèšããŸãããæ£è ãããšå¯æ¥ã«é£æºããããšã§ãæ£è ãããæ²»éšã®äžå¿ã«æ®ãããšãããã¬ã¯ã»ã«ã®ããã·ã§ã³ãæšé²ãç¶ããŠããŸãã圌女ã®åœ¹å²ã¯ãå¥åº·å¿çåŠãã€ãããŒã·ã§ã³ãæ£è ãšã³ã²ãŒãžã¡ã³ãã®çµéšãèåããããã®ã§ãããæ¥çãæ£è äžå¿ã®å®è·µãç¶ç¶çã«æ¹åããŠããããšã«è²¢ç®ã§ããããšã«åã³ãæããŠããŸãã
äž»åžå¯é·å®ãšããŠããšã€ããŒã»Pã»ã¢ããã·ãŒå士ïŒå»åŠå士ãPh.D.ïŒã¯ãFDAã®æ¥åžžæ¥åãç£ç£ããå»è¬åãå»çæ©åšããã°ããé£åã®èŠå¶ãç£ç£ãããªãã£ã¹ã暪æããŠãç¹å¥ãã€åªå 床ã®é«ãã€ãã·ã¢ãããææ®ããŠããŸãã
ã¢ããã·ãŒå士ã¯ãè¡æ¶²åŠè ïŒè «çåŠè ã§ãããç·©åå»çå°éå»ã§ããããåœéçã«èªããããèšåºããŒã¿ã®å°é家ã§ãããèšåºç 究è ã§ããããŸããã¢ããã·ãŒå士ã®å°éåéã¯ãããããŒã¿ãå®äžçã®ãšããã³ã¹ãèšåºè©Šéšãå»çãµãŒãã¹ç 究ãæ£è å ±åã¢ãŠãã«ã ïŒPROsïŒãèšåºæ å ±åŠãæ£è äžå¿ã®ã±ã¢ãªã©å€å²ã«ããããŸãã
FDAã«æ¥ãåã¯ããã©ããã¢ã€ã¢ã³ã»ãã«ã¹ç€ŸïŒãã·ã¥ã»ã°ã«ãŒãã®äžå¡ïŒã§æé«å»ç責任è ãæé«ç§åŠè²¬ä»»è ãè «çåŠæ åœäžçŽå¯ç€Ÿé·ãåããè «çåŠç 究ãèšåºæ¥åãããŒã¿ãµã€ãšã³ã¹ããŒã ãçããå®äžçã®ãšããã³ã¹ã«åºã¥ãç 究ããžã§ã³ã®æå°ãªã©ãå瀟ã®å šäœçãªæŠç¥çããžã§ã³ã«è²¢ç®ããŠããŸããã
ãã以åã¯ããã¥ãŒã¯å€§åŠå»åŠéšã®å»åŠææãåãããã¥ãŒã¯èšåºç 究æã®ãã©ãŒãã³ã°ã»ãã«ã¹ã±ã¢ã»ã»ã³ã¿ãŒããšãã¥ãŒã¯ããç 究æã®ããã¥ãŒã¯ããã±ã¢ç 究ããã°ã©ã ããéå¶ããŠããŸããããã¥ãŒã¯å€§åŠã§ã¯ããããçåœãè ããé節ãªçŸæ£ãæã€äººã ã®ã±ã¢ã«æ°ããªé²æ©ãããããããã®æè¡ãã©ãããã©ãŒã ã®éçºã«å é§çã«åãçµãã§ããŸããã
ã¢ããã·ãŒå士ã¯ãç±³åœå»åŠã¢ã«ãããŒã®å šç±³ããæ¿çãã©ãŒã©ã ã®ä»»åœã¡ã³ããŒãç±³åœèšåºèª¿æ»åŠäŒã®éžåºã¡ã³ããŒãç±³åœãã¹ãã¹ïŒç·©åå»çåŠäŒã®å äŒé·ãåããçµéšããããŸãã
ã¢ããã·ãŒå士ã¯ããã¥ãŒã¯å€§åŠã§å»åŠå士å·ãååŸããå ç§ã¬ãžãã³ããããŒãã¬ãžãã³ããåããè¡æ¶²åŠïŒè «çåŠãã§ããŒã·ãããä¿®äºããŸããããªãŒã¹ãã©ãªã¢ã®ããªã³ããŒã¹å€§åŠã§ãšããã³ã¹ã«åºã¥ããå»åŠãšèšåºæ å ±åŠã«çŠç¹ãåœãŠãå士å·ãååŸãããã³ã·ã«ããã¢å€§åŠã§åŠå£«å·ãååŸããŸããã
Bhooshi de Silvaã¯ãPPDã®äŒæ¥éçºãæŠç¥ããã³ãã£ãŒã®ã°ããŒãã«ããããåããŠããŸãããŸãããã·ã«ãã¯ãå瀟ã®ãšã³ã¿ãŒãã©ã€ãºããŒã¿æ©èœããªãŒããããã³ãã£ãŒããŒãããŒã·ããã管çããŠããŸãã圌ã¯ãäž»èŠãªæŠç¥çã€ãã·ã¢ããã§ã·ãã¢ãªãŒããŒã·ããããŒã ãšååããPPDã®ããŒã¿ãšç Žå£çã€ãããŒã·ã§ã³ã®åªå äºé ããªãŒãããäŒç€Ÿã®é²åãšæé·ãæšé²ããäžã§éèŠãªåœ¹å²ãæãããŠããŸããPPDã«å ¥ç€ŸããŠä»¥æ¥ããã»ã·ã«ãã¯çµç¹ãçããŠãããã€ãã®æŠç¥çããŒãããŒã·ãããè²·åãå®äºãããéç¹åéã«ãããäŒç€Ÿã®èœåã匷åã»æ¡å€§ããŠããŸããã
ãã»ã·ã«ãã¯ãPPDã«å ¥ç€Ÿããã«ãããããã€ãªå»è¬åæ¥çã§15幎ã®çµéšãæã£ãŠããŸãããã¡ã€ã¶ãŒã§ãã£ãªã¢ãã¹ã¿ãŒããããç 究éçºããŒããã©ãªãªç®¡çãç±³åœã§ã®åæ¥éçºãç±³åœã®é¡§å®¢æŠç¥ãšäº€æžãªã©ãæ åœããŸããã2009幎ã«ã¯ãäºæ¥éçºè©äŸ¡ã»æŠç¥æ åœå¯ç€Ÿé·ã«å°±ä»»ããã©ã€ã»ã³ã·ã³ã°ãè²·åãäŒæ¥æŠç¥ã€ãã·ã¢ããã®è©äŸ¡ãæ åœããããŒã ãçããŸããããã®åŸããªããã£ããŒç€Ÿã§ã¯ãäŒæ¥éçºãäŒæ¥æŠç¥ãåœééšéã®è²¬ä»»è ãåããŸãããåæ¥åæŠç¥ãšOptimer瀟ã®Cubist Pharmaceuticals瀟ãžã®å£²åŽã«ãããŠéèŠãªåœ¹å²ãæããããäŒæ¥ã®æŠç¥çã€ãã·ã¢ãããM&Aã®å®çžŸãè±å¯ã
Anshul Thakralã¯PPDã®æé«åæ¥è²¬ä»»è ãåããŠããŸãã圌ã¯2016幎ã«PPDã®çµå¶é£ã«å ããããžã§ãã©ã«ãããŒãžã£ãŒãçµå¶ã³ã³ãµã«ã¿ã³ããèµ·æ¥å®¶ãšããŠè£œè¬ã»ãã€ãªãã¯ãããžãŒæ¥çã§20幎è¿ãã®çµéšãæã¡ãå瀟ã®ãã€ãªãã¯ãããžãŒé¡§å®¢ã»ã°ã¡ã³ããçããŠããŸãã2019幎ã«ã¯ãPPDã®äž»èŠãªé¡§å®¢ã»ã°ã¡ã³ãã§ãããã€ãªãã¡ãŒããšãã€ãªãã¯ãããžãŒã®äž¡æ¹ã®åæ¥ç責任ãå šé¢çã«æ ãããã«è²¬ä»»ãæ¡å€§ããŸããã
PPDã®åã«ã¯ãThakralã¯Gerson Lehrman GroupïŒGLGïŒã§ã°ããŒãã«ã©ã€ããµã€ãšã³ã¹äºæ¥éšãéå¶ãã補è¬ã»ãã€ãªãã¯ãããžãŒæ¥çã«ãµãŒãã¹ãæäŸãã顧客ããžãã¹ã¢ãã«ãæ§ç¯ããŠããŸãããGLG以åã¯ãMcKinsey & Companyã§ãã«ã¹ã±ã¢äºæ¥ã®ã¢ãœã·ãšã€ãããªã³ã·ãã«ãšããŠãæé·ãæŠç¥ãç 究éçºãäºæ¥éçºãåžå Žåå ¥ã¢ãããŒããåæ¥ã¢ãã«ãªã©ã®éèŠãªãããã¯ã«ã€ããŠãã°ããŒãã«ãªè£œè¬ã»ãã€ãªãã¯ãããžãŒäŒæ¥ã®äžçŽç®¡çè·ãCEOã«ã«ãŠã³ã»ãªã³ã°ãè¡ã£ãŠããŸããã
ãžã§ã³ãºã»ãããã³ã¹å€§åŠã§çç©å»åŠå·¥åŠã®åŠå£«å·ãšä¿®å£«å·ãååŸãããã³ã·ã«ããã¢å€§åŠãŠã©ãŒãã³ã¹ã¯ãŒã«ã§MBAãååŸããŸããã
Darshan Dalal ã¯ã倧åŠãšè£œè¬æ¥çã®äž¡æ¹ã§çµéšãç©ãã å»åž«ã»ç«åŠè ã§ãã10幎以äžã«ãããæ§ã ãªåœ¹å²ãæ ããçŸåšã¯Novartis Oncology瀟ã§æ§ã ãªååç©ã®åæéçºããã³åŸæéçºããªãŒãããŠããŸãã第Içžãã第IVçžãŸã§ã®ããã€ãã®èšåºè©Šéšããã°ã©ã ãã¬ãžã¹ããªãŒãRWEãäž»å°ããŠããçµéšãããèšåºç 究ã®æ¹æ³è«ã匷åããèšåºäžã®çåã解決ããçŸæ£ãšãã®æ²»çã«é¢ããç解ãæ·±ããããã®æ°ããæè¡ãå°å ¥ããæ¹æ³ã®éçºã«èå³ãæã£ãŠããŸãããžã§ã³ãºã»ãããã³ã¹å€§åŠå»åŠéšã»å ¬è¡è¡çåŠéšããžã§ãã³ããã¯ãããã«ãã£ã¹ãAdvanced Accelerator ApplicationsïŒããã«ãã£ã¹ç€ŸïŒã§ã¯ãå¿ççãå¿æ¿çŽ°åããã¿ãã³ãµããªã¡ã³ããæ ¢æ§è èç ãä¹³ãããå€§è žãããèºãããåç«è ºãããæªæ§è¡æ¶²åŠãã²ããã¯ã¹ãããããªãã¯ã¹ãã¡ã¿ãããã¯ã¹ãªã©ã®çŸæ£åéã§å¹ åºãç 究ãè¡ã£ãŠããŸããããŸããå€ãã®ç§åŠéèªã®æ»èªè ãåããŠããŸãã
ãã¹ã«ã«ã»ããã¹ã¯ãæè³éè¡ãã³ã³ãµã«ã¿ã³ãäŒç€Ÿã§æŠç¥ãšæè¡é©æ°ã®ãããžã¡ã³ãã«è±å¯ãªçµéšãç©ãã åŸã2001幎ã«ãããœãŒã»ã·ã¹ãã ãºã«å ¥ç€Ÿããç 究éçºæ åœå¯ç€Ÿé·ãšããŠå¶æ¥éçºãæ åœããŸããããã®åŸãæŠç¥ã»äºæ¥éçºæ åœå¯ç€Ÿé·ïŒ2003幎ïŒãæŠç¥ã»ããŒã±ãã£ã³ã°æ åœäžçŽå¯ç€Ÿé·ïŒ2007幎ïŒãçµãŠãçµå¶æŠç¥ã»åžå Žéçºæ åœäžçŽå¯ç€Ÿé·ïŒ2010幎ïŒããã©ã³ãã»äŒæ¥éçºæ åœäžçŽå¯ç€Ÿé·ïŒ2014幎ïŒã«å°±ä»»ããŸããã2018幎ãæé«è²¡å責任è å Œçµå¶æŠç¥è²¬ä»»è ã«å°±ä»»ã2020幎ããæé«å·è¡è²¬ä»»è å Œæé«è²¡å責任è ããã¹ã«ã«ã»ããã¹ã¯æé«å·è¡è²¬ä»»è ãšããŠããªãã¬ãŒã·ã§ã³ãºå·è¡å§å¡äŒãçããŠãå瀟ã®ãã¹ãŠã®æŠç¥çæ©èœã®ãªãã¬ãŒã·ã§ã³ã¬ãã«ã§ã®ææ決å®ãææ®ããçµæžã®3ã€ã®æŠç¥çã»ã¯ã¿ãŒã§äžçã®ãªãŒããŒãšãªãããšãç®æããŠããŸãããã¹ã«ã«ã»ããã¹ã¯ã補é æ¥ãã©ã€ããµã€ãšã³ã¹ãšãã«ã¹ã±ã¢ãã€ã³ãã©ã¹ãã©ã¯ãã£ãŒãšå°åã®3ã€ã®æŠç¥çã»ã¯ã¿ãŒã§äžçã®ãªãŒããŒãšãªãããšãç®æããŠããŸãããã¹ã«ã«ã»ããã¹ã¯2020幎ããåç· åœ¹äŒã®ã¡ã³ããŒã«ãªã£ãŠããŸãããã¹ã«ã«ã»ããã¹ã¯ãç Žå£çãªãã¯ãããžãŒãšç€ŸäŒã®é²åã¯å¥åã®ãã®ãšããŠã¢ãããŒãããããšã¯ã§ããªããšãã確åºãã信念ã®ããšãæ°ããåéãéæãããšãããããœãŒã»ã·ã¹ãã ãºã®æ¹éã«éèŠãªè²¢ç®ãããä»æ¥ã®ãããªç¬èªã®ããŒã±ããã«ãã¬ããžãå®çŸããŸãããå°æ¥ã®ãã¬ã³ããåãå ¥ããæãç¬åµçãªæèœãçµéããèœåãæã€ãã¹ã«ã«ã»ããã¹ã¯ãæ¥åç¥èãæè¡çå°éç¥èãéãè²·åæŠç¥ãçµã¿åãããŠããããœãŒã»ã·ã¹ãã ãºã®çºå±ã®ããã«æ©èœæšªæçãã€åŠéçãªã¢ãããŒããåã£ãŠããŸãããã¹ã«ã«ã»ããã¹ã¯ãèšåºè©Šéšã®äžççãªãŒããŒã§ããããããœãŒã»ã·ã¹ãã ãºã®ãã©ã³ãã§ãããã¡ãã£ããŒã¿ã®äŒé·ãšããããœãŒã»ã·ã¹ãã ãºãèšç«ããã¯ã©ãŠããµãŒãã¹äŒç€Ÿ3DS OUTSCALEã®ç€Ÿé·ãåããŠããŸãããŸãããã©ã³ã¹æ¿åºãæ¯æŽããã¯ãªãšã€ãã£ãç£æ¥ã€ãã·ã¢ããã®å ±åè°é·ãåããŠããŸãã
Shari ã¯ããã¹ãã³ã»ãµã€ãšã³ãã£ãã£ãã¯ã®ãªãºã ãããžã¡ã³ãã®èšåºãããžã§ã¯ã管ççµç¹ã®ããªã³ã·ãã«ã»ããžãã¹ã»ã¢ããªã¹ãã§ãã圌女ã¯å»çæ©åšæ¥çã§27幎éå€åããŠããããã¹ãã³ã»ãµã€ãšã³ãã£ãã£ãã¯ãšã¡ãããããã¯ã®äž¡æ¹ã§20幎以äžã®èšåºçµéšãããããªãºã 管çãšæ§é å¿èéšéã§åããŠããŸãããéšéãè¶ ããŠååçã«ä»äºãããŠãããèšåºããã»ã¹ã®ããã€ãã®åéãç¹ã«ããŒã¿ç®¡çãã»ã³ãã©ã«ã¢ãã¿ãªã³ã°ããã¯ãããžãŒãœãªã¥ãŒã·ã§ã³ã®å°éç¥èãæã£ãŠããŸãããŸãããããžã§ã¯ã管çã®çµéšããããã€ãããŒã·ã§ã³ãžã®æ ç±ãæã¡ãeConsent ã®å°å ¥ãæšé²ããŠããŸããã
Medidata ã§äœ¿çšããã¯ãããŒãéžæããŠãã ãã
ãŠãŒã¶ãŒèšå®ã¯ 6 ãæéä¿æãããå Web ããŒãžã®ããã¿ãŒã®ããŠãŒã¶ãŒèšå®ã®ç®¡çããªã³ã¯ãã¯ãªãã¯ãããšãã€ã§ãå€æŽã§ããŸããæ¬ãµã€ãã«ãããã¯ãããŒã®äœ¿çšã®è©³çŽ°ã«ã€ããŠã¯ãåœç€Ÿã® å人æ å ±ç®¡çæ¹éãã芧ãã ããã
ã¯ãããŒãåå¥ã«éžæ
éžæããèšå®ã¯ 3DS 㧠6 ãµæéä¿æãããŸãããã®æéãçµäºãããšã3DS ã¯å床ãŠãŒã¶ãŒã®åæãæ±ããŸãã
- Microsoft Clarity
- Microsoft Bing
- Mouseflow
- Oracle / Eloqua
- 6sense
- Autodesk